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Background and Aims 
Early diagnosis of prostate cancer and improvement in treatment and palliative care 
has translated in more men living with prostate cancer for prolonged periods of time. 
The current thesis therefore assessed clinical outcomes for men diagnosed with 
prostate cancer by specifically focusing on those outcomes related to the disease itself 
and those related to prostate cancer-specific treatments. 
 
Methods 
1) Disease-related Outcomes 
a. Serum biomarkers and second primary tumours:  
The Swedish AMORIS cohort was used to investigate how a variety of serum 
biomarkers of different metabolisms (i.e. glucose, lipids, gamma-glutamyl transferase 
(GGT) and fructosamine) measured before prostate cancer diagnosis as a first primary 
tumour, are associated with patterns of secondly diagnosed primary tumours (SDPTs). 
This database contains information on >350,000 men who provided measurements for 
these biomarkers. Cox proportional hazard models and multiple imputations were 
used to quantify these associations. 
 
2) Treatment-related Outcomes 
For the next three projects, I used the PCBaSe Sweden database which covers >96% of 
prostate cancer patients in Sweden between 1998 and 2006. 
b. The association between radiotherapy and risk of thromboembolic disease:  
Using Cox proportional hazard models, I investigated the risk of thromboembolic 
disease (TED) after receiving radiotherapy for prostate cancer. 
c. Drugs for metabolic conditions and prostate cancer death in men on gonadotropin 
releasing hormone receptor agonists: 
I investigated how having a treatment for metabolic disease-related components 
(‘metabolic drugs’) at the time of androgen deprivation therapy initiation was 
associated with prostate cancer mortality and overall mortality. Cox proportional 




d. Anti-androgens versus on gonadotropin releasing hormone receptor (GnRH) agonists 
in relation to prostate cancer death: 
Using propensity score matching, Cox proportional hazard models and cumulative 
incidence analyses, I investigated whether there is any difference in terms of prostate 




My findings in the AMORIS study support the hypothesis that alterations in metabolic 
factors like cholesterol, triglycerides and GGT present several years before prostate 
cancer diagnosis may indicate a common biological background between prostate 
cancer and SDPTs. In more detail, my results showed higher risk of SDPTs for those 
with high serum levels of triglycerides (HR: 1.37, 95%CI: 1.17-1.60), total cholesterol 
(HR: 1.22, 95%CI: 1.04-1.42) and GGT (HR: 1.32, 95%CI: 1.02-1.71), as compared to the 
normal levels. 
 
My findings in the PCBaSe studies show that: 
a. After adjusting for all available confounding covariates, no association was 
found between radiotherapy (in the forms or external beam radiotherapy and 
brachytherapy) and TED (HR: 1.05, 95% C.I.: 0.61-1.79 and HR: 0.97, 95%C.I.: 
0.29-1.44 respectively). Radiotherapy was not associated with an increased risk 
of thromboembolic events within 5 years of receiving this treatment. 
b. After competing risk analysis, I observed that ‘metabolic drugs’ did not improve 
or worsen prostate cancer mortality amongst men being treated with GnRH 
agonists. However, men on ‘metabolic drugs’ were more likely to die of 
cardiovascular disease than men not on these drugs (i.e. HR 1.87; 95%CI: 1.56-
2.24 for anti-hypertensive drug use and HR 2.46; 95%CI: 2.03-2.98 for anti-
hypertensive + lipid lowering drug use).  
c. Following propensity score matching, men on GnRH agonists had a similar risk 
of death from prostate cancer as men on anti-androgens, HR 1.09 (95% CI: 




1.37). Anti-androgens showed similar overall and prostate cancer mortality 
rates to GnRH agonists. 
 
Conclusion 
Overall, my results showed that metabolic alterations in terms of high levels of lipids 
and GGT might have an impact on men after prostate cancer diagnosis by an 
association with an increased risk of SDPTs. However, treatment for metabolic 
syndrome related conditions did not increase the risk of prostate cancer death 
amongst those treated with GnRH agonists, but did increase the risk of CVD-related 
deaths.  Also, my results help elucidate potential treatment side-effects and outcomes 
by showing that: a. radiotherapy did not increase the risk of TED, allowing patients and 
physicians to focus on other well-established RT side effects (i.e. erectile dysfunction, 
urinary incontinence or bowel incontinence); and b. that anti-androgens may be an 
alternative to GnRH agonists for men with advanced non-metastatic prostate cancer, 
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1. Chapter I: Introduction and research objectives 
Prostate cancer is the second most common cancer in men, with almost 70% of the 
cases occurring in more developed regions. Prostate cancer incidence varies greatly 
worldwide with the highest rates being reported in Oceania, North America, western 
and northern Europe, followed by less developed regions, such as the Caribbean, 
southern Africa and South America. The lowest rates are found in Asian populations 
(1). 
 
Established risk factors include black race, older age and family history. However, an 
increasing body of evidence suggests that Westernized lifestyle can also increase the 
risk of having prostate cancer. For instance, migration studies have shown that after 
migration to the United States of America, Chinese and Japanese show substantial 
increase in prostate cancer incidence (2). 
 
Even though prostate cancer represents the fifth leading cause of death from cancer in 
men, overall mortality rates are decreasing. These trends translate into men living 
longer with prostate cancer diagnosis – which is thought to be mainly attributed to the 
introduction of prostatic specific antigen (PSA) testing (see below: PSA-screening) (3).  
Five-year survival rates can be more than 90% in some countries (e.g. 99% in the 
United States of America). However, as encouraging as these numbers are, living with 
prostate cancer entails several health consequences related to the disease itself as 
well as its treatments (4).  
 
This thesis therefore aims to provide more insight into the impact of a prostate cancer 
diagnosis and its treatments on a man’s quality and quantity of life by investigating 
different disease and treatment-related clinical outcomes. More specifically, this thesis 
comprises of the following four projects: 
 
(1) Using the Swedish AMORIS study, I investigated how a variety of serum 




diagnosis were associated with patterns of secondly diagnosed primary 
tumours (SDPTs).  
(2) Using data from PCBaSe Sweden, I evaluated how radiotherapy for prostate 
cancer is associated with risk of thromboembolic disease (TED).  
(3) In the same database, I assessed the association between drugs used to treat 
symptoms of the metabolic syndrome and prostate cancer death among men 
on primary Gonadotropin-releasing Hormone (GnRH) agonists.  
(4) Finally, I compared prostate cancer-specific and overall survival between men 
treated with primary anti-androgen monotherapy (AA) and GnRH agonists 
using data from PCBaSe Sweden. 
 
The next chapter provides an overview of the current state of the art with respect to 
prostate cancer epidemiology and outcomes – with specific focus on the four projects 
described above. The methods and results of the first project are described in Chapter 
III, whereas the other three projects are all described in Chapter IV. Finally, chapter V is 






2. Chapter II: Background 
2.1. The normal prostate: Anatomy, histology, physiology  
A normal prostate gland is approximately 20 to 30 g in volume and has the shape of a 
chestnut. It is located posterior to the pubic symphysis, under to the bladder, and 
anterior to the rectum. The prostate surrounds part of the urethra (prostatic urethra) 
which explains some of the common symptoms reported for prostate pathologies such 
as urine retention, decreased force of stream or urinary frequency.(5)  
 
Prostate tissue consists of 70% glandular tissue and 30% fibromuscular-stroma and can 
be divided into three zones (Figure 1):  
The transition zone: represents 10% of the prostatic glandular tissue and 20% of the 
adenocarcinomas can be found in it. 
The central zone: surrounds the ejaculatory ducts and 25% of the glandular tissue. 1-
5% of adenocarcinomas can be found in this zone. 
The peripheral zone: represents 70% of the glandular tissue. It is located in the 
posterior and lateral segments of the prostate. About 70% of the adenocarcinomas are 









The prostate’s main function is the production of a fluid that gives a liquid consistency 
to semen with the necessary properties that will provide spermatozoids good motility, 
protection and prolonged survival.  
 
In order to develop and function, prostate cells need androgens: testosterone and its 
more active metabolite dihydrotestosterone (DHT) converted to by the enzyme 5a-
reductase in the prostate (7). These hormones are part of a well-described endocrine 
feedback loop. Simplified, the hypothalamus produces Gonadotropin Releasing 
Hormone (GnRH), which acts on the pituitary gland cells. These cells release luteinizing 
hormone (LH) and follicle stimulant hormone (FSH). LH and FSH act on the testis, 
where they promote the synthesis and liberation of androgens and inhibin. These two 
molecules have effects on different tissues and a negative feedback effect on the 
hypothalamus and the pituitary gland, which as a result downregulates the synthesis 
of androgens (8). Once in the prostate cells, testosterone and DHT bind to the 
androgen receptor (AR) located on nuclear membrane, which acts as a transcription 











2.2. Prostate Cancer 
2.2.1. Clinical presentation 
Currently, most prostate cancers are diagnosed in men who are asymptomatic. This is 
due to screening programs where a molecule found in prostate cells, the prostatic 
surface antigen (PSA- see below), is measured in blood.  Usually these patients present 
local disease. However, for those with more advanced disease common symptoms go 
from urinary complaints to weight loss, bone pain, neurologic alterations due to spinal 
cord compression and other symptoms of metastasis. During physical examination, 
physicians perform a digital rectal examination (DRE) in order to determine size, 
consistency and detect any abnormalities on the posterior surface of the prostate. This 
procedure complements further studies for clinical staging of the disease.  
 
Once prostate cancer is suspected, either by elevated blood levels of PSA, physical 
examination or by symptoms, a prostate biopsy is usually the confirmatory test where 
different histological characteristics are scored according to the grade of cell 
differentiation, meaning how much tumour cells resemble the normal prostatic tissue. 
The less alike the tumour cells look compared to the normal prostatic cells the less 
differentiated the cancer is considered. The standardized scoring system based on 
these microscopic characteristics is the Gleason score. The score is based on the sum 
of the grades of the two most common tumour cells patterns. Gleason grade ranges 
from 1 to 5 and the Gleason score ranges from 2 to 10. Higher grades and scores 




Figure 3 Gleason’s pattern (10) 
 
 
Recently Eppstein et al. introduced the following grading system (Figure 4): 
 Grade group 1 (Gleason score 3 + 3 = 6): Only individual discrete well-formed 
glands. 
 Grade group 2 (Gleason score 3 + 4 = 7): Predominantly well-formed glands 
with lesser component of poorly formed/fused/cribriform glands  
 Grade group 3 (Gleason score 4 + 3 = 7): Predominantly poorly formed/ 
fused/cribriform glands with lesser component of well-formed glands*.  
 Grade group 4 (Gleason score 8): only poorly formed/fused/cribriform glands 
or - Predominantly well-formed glands and lesser component lacking glands ** 
- Predominantly lacking glands and lesser component of well-formed glands ** 
 Grade group 5 (Gleason scores 9–10): Lack of gland formation (or with necrosis) 
with or without poorly formed/fused/cribriform glands*(11) 
*For cases with >95% poorly formed/fused/cribriform glands or lack of glands on a core or at radical prostatectomy, 
the component of <5% well- formed glands is not factored into the grade. 











Due to this change in GS grading, many prostate cancers have been reclassified to a 
higher grade in what is known as stage migration or the “Will Rogers phenomenon” 
(Figure 5) (12). Studies assessing this effect in prostate cancer have shown an artificial 
improved survival for prostate cancers both previously classified as low grade and high 
grade. This occurs because among those prostate cancers that were historically 
classified as low grade, there were some of a higher grade according to the new 
grading system which probably had a lower survival than those who were classified as 
a low grade in both systems (13). Thus, by including those who had a higher grade and 
lower survival, the lower grade group’s survival improves. The same occurs by adding 
those previously classified as low grade to the newly higher grade, assuming that they 
had a better survival than those who had been classified from the beginning as a high 
grade. Consequently, survival seems to improve across the new grading system, which 
in many instances has been attributed to improvement in treatment modalities (14). 
Although important to acknowledge, this phenomenon does not affect the results in 
this thesis, as survival or other clinical outcomes were not assessed between men 
diagnosed in these different time periods. 
 





Based on the biopsy results and the PSA values, imaging studies may be performed to 
assess macroscopic tumour characteristics. The TNM Classification of Malignant 
Tumours is then used, where T stands for tumour size and infiltration of nearby 
structures, N for lymph node invasion and M for distant metastasis (Table 2).  
Using several parameters such as age at diagnosis, PSA, Gleason score, TNM 
classification and percentage of positive biopsy cores, different prediction models and 
risk categories have been created to aid clinicians and patients with treatment 
decisions (15) (Table 1). Tissue based molecular assays are available for 
prognostication in prostate cancer; these can distinguish between low and 
intermediate risk disease (i.e. Oncotype DX, Prolaris). Currently they are only used in 
the US (16). 
Table 1. European Urology Association prostate cancer risk assessment (17) 
Definition 
Low-risk Intermediate-risk High-risk 
PSA < 10 ng/mL 
and GS < 7 (ISUP grade 
1) 
and cT1-2a 
PSA 10-20 ng/mL 




PSA > 20 ng/mL 




any GS cT3-4 or cN+ 
Any ISUP grade 
Localised Locally advanced 
GS=Gleason score; ISUP=International Society for Urological Pathology;  
PSA=prostate-specific antigen.  
Recently an increasing body of evidence indicates that multiparametric MRI before 
biopsy and MRI guided biopsy may improve prostate cancer detection in particular 
those considered clinically significant (18-20). Although some studies have not shown 
the superiority of an MRI protocols over ultrasonography–guided biopsies (21, 22) a 
recent RCT, the PRECISION (Prostate Evaluation for Clinically Important Disease: 
Sampling Using Image Guidance or Not?) trial, has shown that MRI, with or without 
targeted biopsy, leads to fewer men undergoing biopsy, more clinically significant 
cancers being identified, less overdetection of clinically insignificant cancer, and fewer 
biopsy cores being obtained than standard transrectal ultrasonography–guided biopsy. 
However, an important limitation of the trial was the moderate agreement (78%) 
between the site and the central radiologist reading, indicating the need for further 
research to improve the standardization, reproducibility, and reporting of 








Table 2. TNM classification of prostate cancer (24) 
T - Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour that is not palpable 
 T1a Tumour incidental histological finding in 5% or less of tissue resected 
 T1b Tumour incidental histological finding in more than 5% of tissue resected 
 T1c Tumour identified by needle biopsy (e.g. because of elevated prostate-specific 
antigen (PSA) level) 
T2 Tumour that is palpable and confined within the prostate 
 T2a Tumour involves one half of one lobe or less 
 T2b Tumour involves more than half of one lobe, but not both lobes 
 T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule1 
 T3a Extracapsular extension (unilateral or bilateral) including microscopic bladder 
neck involvement 
 T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external 
sphincter, rectum, levator muscles, and/or pelvic wall 
N - Regional Lymph Nodes2 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M - Distant Metastasis3 
M0 No distant metastasis 
M1 Distant metastasis 
 M1a Non-regional lymph node(s) 
 M1b Bone(s) 
 M1c Other site(s) 
1Invasion into the prostate apex or into (but not beyond) the prostate capsule is not classified as T3, but as T2. 
2Metastasis no larger than 0.2 cm can be designated pNmi. 
2T2a to c only exist for clinical T2 (cT2). For pathological T2 they are no longer present in the 2017 TNM. Only pT2 exists. 







2.2.2. Prostate cancer biology and natural history 
About 95% of all prostate cancers are adenocarcinomas; followed by 4% that present 
transitional cell characteristics and are believed to develop from urothelial cells form 
the prostatic urethra. The remaining few cases are either neuroendocrine or squamous 
cell carcinomas (15).   
 
Prostate cancer, in most cases, is a slow growing tumour detected in adults and elderly 
adults. Prostate cancer is likely to be, as many other cancers, the result of various 
genetic hits that occur over many years. Therefore, lifestyle and environmental risk 
factors are thought to also impact prostate cancer development and progression 
throughout most of men’s life.  
 
Different studies have looked at associations between the exposure to some factors in 
utero and prostate carcinogenesis. For instance, birth weight has been used in some 
studies as a proxy for nutrients and other exposure factors during pregnancy. 
However, results are inconsistent (7). Nonetheless, lack of consistency between 
studies does not rule out a possible association. In Rothman’s sufficient cause model 
different component causes may add up to different sufficient causes for the same 
outcome. Meaning that depending on the context and the population, some of these 
factors can be associated or not with the outcome. Furthermore, temporality and 
other exposures to potential preventive factors need to be taken into account (25). 
Extreme hormonal changes that occur during adolescence have also been suggested as 
possible elements that predispose to genetic alterations that together with other 
factors that occur later in life, even aging itself, lead to prostate cancer carcinogenesis. 
It is well established that androgens are necessary for prostate cancer development.  
In laboratory studies prostate cancer growth is inhibited in the absence/ blockage of 
androgens and stimulated in their presence. Furthermore, one of the current 
treatment protocols for prostate cancer, androgen deprivation therapy (ADT), consists 
on lowering levels of androgens by chemical or surgical castration. However, many 
prostate cancers become androgen resistant or refractory tumours, and although they 
still show activity in response to androgens, lack of these hormones does not stop 




changes in the androgen receptor that lead to its downstream activation in the 
absence of a ligand (26). 
 
2.2.3. Descriptive epidemiology 
2.2.3.1. Incidence  
Prostate cancer is the second most commonly diagnosed male cancer worldwide. 
However, these worldwide incidence rates are strongly influenced by large Asian 
populations where the most common cancer is of the lung. When looking at Europe, 
North and South America, Oceania and most of Africa, the most commonly diagnosed 
cancer is prostate cancer. Part of these variations in incidence rates across populations 
can be attributed to differences in PSA screening (see below) access and/or 
recommended protocols and a smaller part due to lifestyle factors (27). For instance, 
globally age standardized incidence rates have increased over time mainly in countries 
where PSA screening has been routinely applied like the US or Europe. Nonetheless, 
incidence rates have also increased in countries from East Asia, where PSA testing has 
not been commonly used (Figure 6). Some researchers have suggested that this could 
be due to a nutrition transition characterized by an increased intake of energy, animal 















In the UK, prostate cancer is the most common cancer among men, accounting for 
about 45,406 cases annually, which represent 27% of all new cancer diagnoses in 2012 
(Figure 7). 
 
Prostate cancer incidence rates have increased by 44% in the UK since the 1990s due 
to the boost in detection with PSA screening. In the last years more than 54% of all 
prostate cancer cases have been diagnosed in men aged over 70 years. Age-
standardized rates for black males are 1.2 to 2.5 times higher than rates for white 
males. Furthermore, lifetime risk of being diagnosed with prostate cancer is 13.2-
15.0% for white males and 23.5-37.2% in black males (29). 
 
In Sweden, prostate cancer is also the most common cancer among men. About 
11,600 new cases were diagnosed in 2012, representing 42% of all newly diagnosed 
cancers (age-standardized incidence rate of 101.9 per 100,000) (Figure 7). PSA 
screening, implemented in 1997, is predominantly responsible for this rapid increase in 





Figure 7 Overview of incidence male cancers in the UK and Sweden in 2012. 
 
 
2.2.3.2. Mortality  
Prostate cancer is the fifth leading cause of death from cancer in men worldwide, the 
second in the UK and the first in Sweden (31). Overall, mortality rates in more 
financially developed regions are decreasing. This is likely due to advances in 
treatment as well as increased detection of early stage disease through PSA testing. 
However, prostate cancer mortality is increasing, as well as incidence, in less resourced 




westernized lifestyle changes and less knowledge and access to curative treatment 
(32). For instance, a recent study using the world’s health organization (WHO) Ranking 
of the World’s Health Systems and the expenditure on health/gross domestic product 
(GDP; e/GDP) and life expectancy showed that prostate cancer mortality to incidence 
ratios (MIR) are higher for less developed countries. This means that besides the below 
described risk factors for prostate cancer, good management of health care (i.e. early 
screenings, advanced surgical and personalized therapy) has a direct impact on 
improving clinical outcomes resulting in low MIRs (33). Prostate cancer survival rates 
vary according to disease stage at diagnosis. For those diagnosed with localised 
disease and low GS prostate cancer, 5-year survival rates are above 90% in most 
countries. However, for those with stage IV (metastatic prostate cancer or GS 8/9) 




2.2.3.3. Prostate cancer screening: PSA and other markers 
PSA is a glycoprotein produced by the prostate gland epithelial cells. Its discovery, 
purification and clinical use are the result of collective contribution by many scientists 
since the late 1960s until the beginning of the 1980s (34). By the mid 1980s, the PSA 
test was first approved by the Food and Drug Administration (FDA) for monitoring 
prostate cancer progression. Later, in 1994, PSA testing was approved for screening 
(35). After the introduction of the PSA test, in most western countries, prostate cancer 
incidence showed a sharp rise and subsequent fall. For instance, in the US this 
occurred between 1989 and 1995 with a peak at 1992, which represents undiagnosed 




Figure 8 Prostate versus lung cancer incidence in the US between 1975 and 2001. (25) 
 
 
Normally, very low levels of PSA can be found in blood. PSA blood levels can increase 
not only due to malignant processes but also due to any inflammatory condition such 
as prostatitis, benign prostatic hyperplasia (BPH) and even after intense exercise or 
recent ejaculation. Increased levels of PSA may indicate the presence of prostate 
cancer. Nonetheless, false negative results are not rare, as prostate cancer can be 
present in the absence of elevated PSA levels (36). Once in the blood stream, most of 
PSA binds to blood proteins and a smaller fraction remains free, also known as fPSA.  
PSA tests using a cut-off of 4.0 ng/mL have a sensitivity of 67.5-80%.  The specificity of 
PSA at levels higher than 4.0 ng/mL is about 60-70% (37). In a prospective blinded 
study by Catalona et al. it was concluded that percentage of fPSA might reduce 




sensitivity in detecting cancer (38). Tests to analyse PSA kinetics are also available. PSA 
velocity (PSAV) is the absolute annual increase in serum PSA (ng/ml/year), 
PSA doubling time (PSADT) measures the exponential increase in serum PSA over time 
and PSA density (PSAD) is calculated dividing serum PSA by prostate volume. Currently 
these measurements have a prognostic application but due to conflicting results they 
are not used in diagnosis (16).  
 
The main aim of screening is to reduce the diagnosis of advanced disease and mortality 
from prostate cancer, while also improving quality of life. Screening should be ethical 
and cost-effective. The PSA test is relatively easy and inexpensive. However, screening 
of asymptomatic men could lead to detection of large numbers of men with latent, 
clinically indolent disease (39). In fact, overdiagnosis rates are estimated to be 
between 27% and 56% due to the lack of specificity of PSA screening. Potential 
benefits and risks or limitations of PSA testing are listed in Table 3. In the last decade 
new PSA, genetic tests and prediction algorithms based on these tests and other 
parameters have been developed. The 4Kscore is a prediction model, which combines 
several variables such as: DRE results, biopsies, age, PSA, fPSA and human kallikrein 2 
in order to predict the patient’s risk of GS ≥ 7 in biopsies (40). Another model is the 
prostate health index (PHI), which combines total PSA, fPSA and serum isoform (-2) 
pro-PSA to predict Gleason Score 7 on biopsy, upgrading/upstaging on prostatectomy 
and recurrence (41). Other blood, urine and tissue based tests are the ‘Stockholm-3’ 
test, the PCA3, the TMPRSS2: ERG and the Mi-Prostate Score (MiPS). All of these tests 
have shown promising results in the prediction of prostate cancer diagnosis and 
progression however they need to be validated in large-scale studies in order to be 






Table 3. Benefits and risks of prostate cancer PSA based screening (modified from (42)) 
 
Benefits Risks or limitations 
1. It may lead to detection of cancer 
before symptoms develop. 
2. It may lead to detection of cancer at 
an early stage when the cancer 
could be cured or treatment could 
extend life. 
3. Repeat PSA tests may provide 
valuable information, aiding a 
prostate cancer diagnosis. 
 
1. The PSA test is not diagnostic. 
2. PSA is not tumour specific in the prostate. 
3. The PSA test may give false-positive results. A 
man may have an elevated PSA level, but no 
cancer. About 75% of men who have an 
elevated PSA level have a false-positive 
result. 
4. The PSA levels may not be elevated and 
provide false reassurance. 
5. The PSA test may lead to the identification of 
prostate cancers, which might not become 
clinically significant. 
 
Thus, the only test that can be found in most prostate cancer guidelines is blood levels 
of PSA. To evaluate the effectiveness of the PSA test in reducing mortality, two 
randomized trials have been conducted and updated: the European randomized study 
of screening for prostate cancer (ERSPC) and the prostate, lung, colorectal, and ovarian 
(PLCO) cancer screening trial.  
 
The ERSPC study randomized 162,388 men for prostate cancer PSA-based screening or 
no screening. Men were between 55 to 69 years of age. Recruitment initiated in 1991 
in the Netherlands and in Belgium, and then between 1994 and 1998 five more 
countries joined: Sweden, Finland, Italy, Spain, and Switzerland. After a median follow-
up time of nine years, the study showed that prostate cancer deaths decreased by 20% 
in men assigned to screening, but there was a high risk of overdiagnosis (43).  For 
instance, the relative risk for prostate cancer between the screening and control 
groups at 9-year follow-up was 1.91, at 11-year follow-up was 1.66, and at a median of 
13 years of follow-up this was 1.57. The most recent update shows that the numbers 
needed to invite for screening to prevent 1 prostate cancer death decreased from 979 
at 9 years to 781 at 13 years and the numbers needed to diagnose to prevent 1 death 




mortality have been reported (44).  This study has been criticized for not publishing de-
identified individual data, in order to confirm the findings. Another point of criticism 
that has been raised is the fact that five of the seven countries included found no 
differences – which questions the validity of data pooling (45). 
 
The PLCO recruited from 10 study centres across the United States, men and women 
between the ages of 55 and 74 years from 1993 through 2001. For prostate cancer 
PSA-based screening, 74,000 men were randomized to either screening or no 
screening. The authors found, after seven to ten years of follow-up, a non-statistically 
significant increase in prostate cancer mortality in the annual screening group (46). 
However, nearly 50% (some claim 90%) of the men in the control group had 
undergone at least one PSA test, and thus the PLCO study does not have the statistical 
power to reach any valid conclusion (47). Yet, in a recent study authors combined data 
from the two trials and performed an analysis in which they took into account 
differences in screening implementation and the settings of both trials. It was 
concluded that both the ERSPC and PLCO trials provide compatible evidence that 
screening reduces prostate cancer mortality (48). 
 
In the UK, the UK National Screening Committee concluded that the evidence to 
support PSA testing as the basis for a screening program is not conclusive, thus their 
recommendation is not to offer screening for prostate cancer. Nonetheless, the test is 
free for men aged 50 or more who request it, on the condition that they receive clear 
and balanced information about the advantages and disadvantages of the PSA test, 
biopsy and treatments for prostate cancer (42). 
 
In Sweden, testing for PSA is not part of a prostate cancer-screening programme. 
Many men have PSA tests on their own initiative. However, a study by Godtman et al. 
found that organized screening reduces prostate cancer mortality and that 
opportunistic PSA testing could result in more overdiagnosis, with almost twice the 
number of men needed to be diagnosed to save one man from dying from prostate 




Hence, the screening debate for prostate cancer has not been solved. Following the 
results of the above described trials it is difficult to disentangle whether the 
overdiagnosis following screening is due to detection of cancers with malignant 
potential, but which have a long lead time, or the diagnosis of truly biologically 
indolent cancers.  
 
However, lack of consistency amongst reference guidelines led a group of prostate 
cancer experts to elaborate a series of consensus statements at the 2013 Prostate 
Cancer World Congress in Melbourne, Australia based on all available evidence. The 5 
statements and brief justifications can be found in table 4 (50). 
 





1. Men Aged 50–69 Years, PSA testing 
reduces the incidence of metastatic 
prostate cancer and prostate cancer-
specific mortality rates. 
Based on evidence from the PLCO, ERSPC and the Götenborg 
studies healthy, well-informed men in this age group should be 
fully counselled about the positive and negative aspects of PSA 
testing to reduce their risk of metastases and death. 
2. Prostate cancer diagnosis must be 
uncoupled from prostate cancer 
intervention. 
Many men with low-risk prostate cancer do not need immediate 
aggressive treatment thus, active surveillance strategies need 
standardization and validation to ensure patients and clinicians 
that this is a safe strategy. 
3. PSA testing should not be considered 
on its own, but rather as part of a 
multivariable approach to early prostate 
cancer detection. 
Ethnicity, family history, medical history, DRE ﬁndings, prostate 
volume, risk prediction models and new tools, such as the 
Prostate Health Index (phi) test and prostate cancer antigen 3 
(PCA3) test, can help to better risk stratify men. 
4. Baseline PSA testing for men in their 
40s is useful for predicting the future risk 
of prostate cancer and Its aggressive 
forms. 
For men whose baseline PSA level is in the highest centiles above 
the median the risk of developing life-threatening disease later in 
life is greater. Thus, this option should be discussed with men in 
this age group. 
5.Older men in good health with a >10-
year life expectancy should not be 
denied PSA testing based on their age. 
 As life expectancy improves in many countries around the world a 
small proportion of older men may beneﬁt from an early diagnosis 
of more aggressive forms of localised prostate cancer. Therefore, 
men should be assessed on an individual basis rather than 
applying an arbitrary chronological age beyond which testing 




PSA concentrations can also be predictive of the future risk of prostate cancer 
metastasis and cancer specific death. In a recent case control study by Vickers et al., 
frozen blood samples were used to select a group of men aged between 27 and 56 
years old. PSA levels were measured and the association between PSA concentrations 
and prostate cancer metastases was analysed. It was found that for men in the highest 
10th of PSA concentration (≥1.3 µg/L) at age 40, the risk of prostate cancer metastases 
after 15 years of follow-up was low (0.6%). However, the risk of metastases within 15 
years was three times higher (1.6%) for men in the highest 10th at age 45-49, and 
close to tenfold higher (5.2%) at age 51-55. They concluded that their results suggest 
that not starting PSA based screening until age 51-55 may translate into an important 
number of men at increased risk of later being diagnosed with an incurable cancer 
(51). 
 
For the current thesis, PSA screening is not affecting the work conducted in the 
Swedish Apolipoprotein-related Mortality Risk (AMORIS) cohort as most cancers were 
diagnosed prior to the introduction of PSA testing (52). The work done using data from 
PCBaSe Sweden (53, 54) focuses on outcomes for men already diagnosed with 
prostate cancer – so that detailed information on tumour characteristics was available 
to account for the potential effects of screening. More details of this work are 
described in Chapters III and IV.   
 
2.2.4. Risk factors 
2.2.4.1. Ageing 
The most important risk factor for developing prostate cancer is ageing; the chance of 
having prostate cancer rises rapidly after age 50. Prostate cancer is often found in 
autopsy studies and most of these men were never diagnosed with the disease (Figure 





Figure 9 Average number of new cases per year and age-specific incidence rates, males, UK, 2012-2014 (56) 
 
 
During aging, there is an increased frequency of DNA damage and of DNA strand-break 
in most of the body tissues. These age-related changes are partly the consequence of 
oxidative stress, characterized by the accumulation of cellular oxidants, such as free 
radicals and reactive oxygen species (ROS). ROS can cause direct damage to DNA as 
well as oxidative modification of proteins, including enzymes involved in DNA repair 
leading to tumourigenesis. Most cells in young, healthy individuals have ROS 




Although several other factors need to be taken into account when making conclusions 
about prostate cancer incidence and mortality in different ethnicities (i.e. socio-
economic status, access to health services and screening programs, health seeking 
behaviour), overall it is considered that black men are at higher risk of presenting and 
dying from prostate cancer when compared to other races (58). Several studies from 
the US and the UK, have shown that men with African ascendance (either American, 
European or Caribbean) are 2.5 to 3 times more likely to develop prostate cancer than 
the Caucasian or Hispanic counterparts. Regarding mortality, black men present 20 to 





It has been shown that the androgen receptor expression is down-regulated in the 
stromal cells of the prostate in black men (60), but has a high expression in malignant 
epithelium (61). Furthermore, it has been suggested that high testosterone levels in 
black men may play a role in the pathogenesis of prostate cancer (62). Another 
possible explanation is the higher prevalence of polymorphisms associated with the 5-
alpha reductase and with the androgen receptor genes which regulate testosterone 
metabolism and function in prostate cancer cells (63). 
 
Diet may also play a role in the difference in incidence of prostate cancer amongst 
different ethnicities. For instance, an epidemiological study showed a positive 
statistically significant association between prostate cancer risk and saturated fat 
intake among all ethnic groups combined. However, fat intake differed among 
different ethnic groups: African-Americans consumed more than white individuals, 
followed by the Asian-Americans (64). 
 
2.2.4.3. Family history and prostate cancer genetics 
First degree relatives of men with prostate cancer are two times more likely to develop 
prostate cancer than the general population. For first degree relatives of men with 
prostate cancer diagnosed at ≤60 years of age this risk is three times or more than the 
risk for men without a family history (Table 5). Furthermore, it has been shown that 
the risk is greater for brothers than for sons of men with prostate cancer, suggesting 
that environmental factors and detection bias may also play a role (65). 
 
Table 5. Effect of family history of prostate cancer on lifetime risk of clinical prostate cancer(65) 
Family History Relative Risk % Absolute Risk 
Negative 1 8 
Father affected at 60 yrs. or older 1.5 12 
1 Brother affected at age 60 yrs. or older 2 15 
Father affected before age 60 yrs. 2.5 20 
One brother affected before age 60 yrs. 3 25 
Two affected male relatives 4 30 





With the advance in molecular biology techniques, several chromosomes and genes 
have been linked to prostate cancer risk. Moreover, evidence suggests that less 
common genetic variants entail higher risk. However, these variants only account for a 
small proportion of the overall familial risk (66). Of particular interest are the single 
nucleotide polymorphisms (SNPs). These are a variation in a single DNA building block, 
called a nucleotide (67). Genome-wide association studies (GWAS) allow the 
simultaneous assay of millions of common (≥5%) SNPs. So far, 100 prostate cancer risk 
related SNPs have been identified which account for approximately 33% of the familial 
risk of prostate cancer in populations of European ancestry (68).  
 
Furthermore, in a recent study using genotype data from men with European and 
African American ancestries, authors found a high degree of similarity between these 
groups suggesting a similar genetic background underlying prostate cancer risk (69). 
Some of the identified regions where SNPs can be found are in chromosomes 8, 10 and 
19. In chromosome 19 SNPs in the genes encoding PSA have been found to affect the 
antigens levels, suggesting a potential role for SNPs mapping in prostate cancer 
screening (66).  
 
Less common variants have also been associated with higher risk of prostate cancer. 
One mutation known to increase the risk of prostate cancer approximately five to 
sevenfold is the one present in the tumour suppressor gene BRCA2. Less evidence has 
been reported regarding BRCA1, although some studies have found that carriers of a 
mutation on this gene have doubled the risk of prostate cancer for males aged <65 
years. Furthermore, a study analysing the role of prostate cancer screening in men that 
had a mutation in either gene, showed that PSA screening had a high positive 
predictive value and that screening amongst these men detected clinical significant 
cancer (70). Germline mutations in the homebox gene HOXB13 are also rare, however 
they have been found to be strongly associated with increased risk of prostate cancer 
(71). Moreover, in a recent study it was found in a cohort of patients with Lynch 
syndrome that their risk of prostate cancer was five times higher than the rest of the 
population, but it did not appear to have earlier onset or a more aggressive 




in one of the mismatch repair genes, increases the risk of colorectal, endometrial, 
ovarian, gastric, small intestinal, pancreatic, ureteral, brain, and sebaceous gland 
adenocarcinomas (72).  
 
Regarding treatment, some researchers used GWAS to look into SNPs and 
radiotherapy response and found that men carrying SNPs in the FSHR (follicle 
stimulating hormone receptor) gene and in chromosome 9 had an increased incidence 
of erectile dysfunction and urinary toxicity, respectively. Furthermore, men who 
underwent radical prostatectomy and had a SNP in the EGFR (epidermal growth factor 
receptor) gene present had less risk of biochemical relapse conferring a protective 
effect (66, 68, 70).  
 
2.2.4.4. Lifestyle factors: Nutrition  
Even though genetic variants explain, in part, the aetiology of prostate cancer and 
some treatment discrepancies between patients, their complex interactions with 
environmental factors are not fully understood yet.  There is a growing body of 
evidence supporting the hypothesis that obesity is associated with increased risk of 
prostate cancer in particular advanced stage, although this association may be biased 
as obese men are less likely to be health conscious and to present a health seeking 
behaviour (i.e. less likely to undergo PSA screening). Furthermore, it has been reported 
that obese men have lower PSA levels due to hemodilution and DRE can be difficult to 
perform and interpret for the practitioners (73). Nonetheless, epidemiological and 
laboratory-based studies have suggested potential biological links between obesity 
and prostate cancer. In a review collecting all available evidence regarding the 
association between obesity and prostate cancer, it was found that three meta-
analyses were in agreement. They all reported weak, but statistically significant 
positive associations. Furthermore, they also reported the results from studies looking 
at obesity and prostate cancer treatment and disease outcomes, and showed that 
obesity was associated with higher risk of biochemical recurrence and prostate cancer 
specific death after radical treatment. Strong and consistent evidence across several 
studies showed a positive dose–response relationship between increasing BMI and 





Regarding specific dietary components, the evidence is less conclusive. Another large 
review reported that results from most studies are either inconclusive or contradictive. 
According to some studies, simple refined carbohydrates might increase the risk of 
prostate cancer by stimulating insulin peaks, insulin resistance and insulin-like growth 
factor-1 (IGF-1)(75). Moreover, this review highlighted that one of the main sources of 
protein for humans, animal meat, may be linked to an increased risk of prostate 
cancer. Some of the mechanisms suggested include the presence of saturated fats and 
cholesterol as well as the formation of heterocyclic amines (HCAs) during high-
temperature cooking. HCAs are compounds that can cause genomic instability through 
DNA damage. Furthermore, consumption of well-cooked meat has been associated 
with increased prostate cancer incidence (76). 
Experimental studies have shown that reducing fat intake slows down tumour growth, 
however human case-control and cohort studies have found no association between 
total fat consumption and prostate cancer risk (77). Yet, in a questionnaire-based 
prospective study, Giovanucci et al. found that total fat consumption, primarily of 
animal origin, was associated with risk of advanced prostate cancer (RR: 1.79; 95%CI: 
1.04–3.07) for high versus low quintiles of intake (78).  
 
Dairy products and calcium intake have also been associated with risk of prostate 
cancer, although the evidence is not conclusive. Results from a study using data from 
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort 
showed that prostate cancer is associated dairy proteins and dairy calcium 
consumption (79). A possible mechanism would be through the downregulation of 
vitamin D by calcium given the high calcium content of dairy. High vitamin D levels may 
regulate gene expression, inhibit cellular proliferation, and induce the differentiation 
of normal and neoplastic cells (80). However, in a nested case-control study within 
EPIC cohorts, no associations were found between serum concentrations of vitamin D 
and prostate cancer suggesting that other mechanisms and factors may also be 





Studies looking at lycopene, vitamin E, cruciferous vegetables, zinc and isoflavones 
have found positive or no associations between these nutrients and prostate cancer 
(15, 82). Lycopene is a carotene found in many fruits and vegetables and its 
consumption has been linked to lower risk of prostate cancer incidence and 
progression. However, in the latest World Cancer Research Fund (WCRF) 
International’s report on diet, weight, physical activity and prostate cancer, the level of 
evidence for lycopene-rich foods was changed from “probable” to “limited, no 
conclusion”. It was clarified that although lycopene has been shown to have strong 
anti-cancer effects in experimental models, currently the data are too mixed to reach a 





Table 6 WCRF levels of evidence regarding diet, weight, physical activity and prostate cancer (83) 
 
 
Yet, as highlighted by Prof Holmberg in his comment on reviews looking into diet and 
prostate cancer, lifestyle markers such as body weight, nutrition, physical exercise and 
socioeconomic status are very closely related and interdependent. Therefore, 
considering all these factors and their effects together in one setting and completely 
deconfounding the analyses in observational studies is rather difficult (84). 
Furthermore, food intake questionnaires can be subject to recall bias, as participants 




answers based on people’s dietary routines, more than on the real consumption. 
Answers are usually influenced by sex, age, and concerns about weight or body image. 
Therefore, for some studies analyses based on physical or chemical measurement (i.e. 
Lipids blood levels) of lifestyle reflectors are likely to be more reliable in order to 
determine the associations between cancer and micro and macronutrients (85-87).  
 
In chapter III, I describe in more detail the current evidence for the associations 
between blood levels of the glucose and lipid metabolism and prostate cancer.  
 
 
2.2.4.5. Physical activity 
Physical activity is associated with lower body fat and testosterone levels, and 
therefore in theory active men should present lower risk of having prostate cancer. 
However, studies results are not consistent and physical activity has been associated 
with decreased and similar prostate cancer risk compared to a sedentary lifestyle (64, 
88). In a more recent systematic review and meta-analysis, 19 cohort studies and 24 
case-control studies were compared to find a significant prostate cancer risk reduction 
for individuals between 20 and 45 years of age (RR: 0.93; 95% CI, 0.89-0.97) and 
between 45 and 65 years of age (RR: 0.91; 95% CI, 0.86-0.97) who performed activities 
as compared to those with limited physical activity, but not for individuals <20 years of 
age or >65 years of age. It was concluded that even though the risk reduction for 
prostate cancer may be small, the benefits of physical activity on other health related 
aspects are well known and thus should be encouraged (89).  
 
2.2.4.6. Cigarette smoking and alcohol consumption 
Cigarette smoking and alcohol consumption have been linked to several different types 
of cancers. Although evidence used to be less conclusive (90) in the last 10 years 
several studies and a meta-analysis have linked cigarette smoking to prostate cancer 
risk (91, 92). Additionally, cigarette smoking has been found to play a further role in 




treatment are more likely to present metastasis, biochemical recurrence or 
progression to castrate resistant prostate cancer than those that cease smoking (93).   
 
Regarding alcohol consumption, previous studies used to show no association 
between this habit and prostate cancer (94, 95). However, more recently an increasing 
body of evidence, which has dealt with type of drinker misclassification bias (i.e., 
former drinkers, occasional drinkers), supports the hypothesis that alcohol may 
increase prostate cancer risk in a dose response manner (96). 
 
2.2.4.7. Chemoprevention 
2.2.4.7.1. 5-Alpha-reductase inhibitors (5-αRIs). 
5-αRIs are used for the treatment of BPH and inhibit the conversion of testosterone to 
DHT. Currently there are two 5-αRIs: finasteride and dutasteride. Both drugs reduce 
the prostate size and levels of PSA (97) and have been assessed in clinical trials for 
their use as prostate cancer chemopreventive agents. The Prostate Cancer Prevention 
Trial (PCPT) evaluated finasteride; after 7 years of follow up those in the finasteride 
arm had a 25 % reduction in prostate cancer incidence (98).  
Dutasteride was studied in the REduction by DUtasteride of prostate Cancer Events 
(REDUCE) trial. Those who received dutasteride had a 23 % reduction in prostate 
cancer incidence after four years of follow up (99).  
However, 5-αRIs are more likely to prevent low-grade cancers with no risk reduction in 
GS ≥7. As previously mentioned, it is unlikely that low-grade cancers lead to prostate 
cancer mortality. It is unknown if this is a result of study design or a real consequence 
of 5-αRIs use. Nonetheless, in 2010, the US FDA Oncology Drugs Advisory Committee 
reviewed the data for finasteride and dutasteride and concluded that the risks of high-
grade cancer were likely to be real and that the trials provided no evidence of a 
reduction in prostate cancer mortality (100).  
 
2.2.4.7.2. Non-steroidal anti-inflammatory drugs  
Experimental studies have shown that prostate cancer is linked to inflammation; 




steroidal anti-inflammatory drugs (NSAIDs)(101). Furthermore, a meta-analysis of 
epidemiological studies showed that aspirin use was associated with a 17% reduction 
in prostate cancer risk. However, authors concluded that data was not conclusive and 
further well-designed observational studies with adequate exposure measurements, 
accurate case definition, attention to latency effects and careful adjustment for 
screening and other biases are needed (102) . 
 
2.2.4.7.3. Statins 
In a recent Nature review on the use of statins and prostate cancer prevention, it was 
concluded that although preclinical research shows that statins can inhibit prostate 
cancer growth and that results from more than thirty observational support the 
hypothesis that statin use reduces the risk of advanced prostate cancer and prostate 
cancer progression, so far no primary prevention trials have been performed to obtain 
the highest possible level of evidence for statins as prostate cancer chemopreventive 
agents. Furthermore, it was highlighted that the results of the observational studies 
may be biased by health-conscious behaviour. Therefore, considering that once 
advanced disease is diagnosed (either by higher GS or metastases), progression occurs 
in a short period of time, implementing secondary and tertiary prevention trials may 
be more feasible and could provide a better insight into the biological actions of statins 
in prostate cancer development (103). 
 
 
2.2.5. Prostate cancer treatments 
2.2.5.1. Deferred treatment: Active surveillance and watchful waiting 
Active surveillance is the periodic monitoring of tumour parameters through repeated 
biopsies, DRE, PSA testing and image studies in men with confirmed low risk localised 
prostate cancer. It is intended to reduce overtreatment in those men whose tumour 
show no or very slow progression, allowing curative treatment when the parameters 
show increased tumour activity or when the patients require it for other reasons (i.e. 




regional guidelines, however the following characteristics are found in most protocols 
(104): 
 Clinically confined prostate cancer (T1–T2) 
 Gleason score ≤6 
 Three or fewer biopsies involved with cancer  
 50% of each biopsy involved with cancer  
 PSA <10 ng/ml 
 
Interestingly, men who fulfil the inclusion criteria for active surveillance after an initial 
biopsy are recommended to undergo a confirmatory biopsy, given that ~30% of 
Gleason scores at initial biopsies are upgraded at confirmatory biopsies (105). 
Indicators to switch to active treatment have also been debated. In the latest report of 
the Prostate Cancer Research International Active Surveillance (PRIAS) study, it was 
concluded that Gleason upgrading and cT3 should be the only indicators for an 
immediate change to curative treatment and that other indicators (e.g., fast-rising 
PSA) should indicate further investigation to confirm the suspicion of higher risk 
disease (106). 
 
In 2016, results from the UK based Prostate Testing for Cancer and Treatment 
(ProtecT) trial were published. In this trial investigators looked at the effects of active 
monitoring, radical prostatectomy, and radical radiotherapy on prostate-cancer 
mortality at a median of 10 years of follow-up. Secondary outcomes included the rates 
of disease progression, metastases, and all-cause deaths. A total of 1,643 men were 
randomly assigned to active monitoring (n=545), radical prostatectomy (n=553), and 
radiotherapy (n=545). Regarding prostate cancer mortality,  no significant difference 
was found among the three randomised groups: there were 17 prostate cancer 
specific deaths overall: 8 in the active monitoring group, 5 in the surgery group and 4 
in the radiotherapy group. Disease progression occurred more in men in the active 
surveillance group, and no significant difference was observed for overall mortality. 




contributed to reassuring practitioners and patients that active surveillance as a valid 
form of treatment for men with low-risk prostate cancer (107). 
 
Watchful waiting is another type of deferred treatment and consist on the observation 
of symptoms and palliative treatment in men diagnosed with prostate cancer who 
have a limited life expectancy due to other comorbidities or in older men with 
localized prostate cancer with less aggressive tumours (104). 
 
2.2.5.2. Curative treatment: radical prostatectomy and radiotherapy 
For men diagnosed with low risk prostate cancer, radical prostatectomy shows similar 
overall survival to conservative treatments (108). However, a study showed that for 
men with intermediate and high-risk disease, radical prostatectomy improved overall 
survival and reduced the risk of bone metastases (104). Furthermore, for intermediate 
and high-risk disease adjuvant hormonal and/or radiation treatment may be used.  
Depending on the T status from the TNM classification, surgeons may also perform a 
pelvic lymph node dissection. In most reference centres of developed countries, 
prostatectomies are being performed with the use of robots a modality known as 
robot-assisted laparoscopic radical prostatectomy (RALP) (104).  
 
Common surgical side effects include: 
 Urinary incontinence, erectile dysfunction 
 Peripheral Neurological Injuries 
 Bowel Complications 
 Rectal, ureteral, bladder Injury 
 Mortality 
 Thromboembolic complications (109). 
 
There are two main types of radiotherapy (RT) for prostate cancer: external beam 
radiation therapy (EBRT) and Brachytherapy. EBRT can be used in earlier stage cancers 
or to help relieve symptoms in more advanced stages. Subtypes of EBRT include: 
 Three-dimensional conformal radiation therapy (3D-CRT) 




 Image guided radiation therapy (IGRT) 
 Stereotactic body radiation therapy (SBRT) used for delivering large doses of 
radiation to a certain precise area, such as the prostate.  
 Proton beam radiation therapy 
 
Brachytherapy is usually applied in early stages of disease and consists of implanting 
small radioactive seeds or pellets in the prostate that will release radiation locally with 
little impact on surrounding tissues (110). 
 
Common side effects for both types of RT include erectile dysfunction, urinary 
incontinence, radiation cystitis, bowel problems/discomfort, tiredness and 
lymphedema (111).  
 
 
2.2.5.3. Hormonal treatment  
Hormonal treatment blocks the endocrine loop that provides the prostate with 
androgens and is therefore also called ADT. It is considered a palliative therapy or 
adjuvant in combination with RP or RT in men with intermediate or high-risk prostate 
cancer. In addition to surgical castration (i.e. orchiectomy), there is also chemical 
castration, which can be achieved through several medications (15): 
 Gonadotropin releasing hormone agonists (GnRH): These aim to reach medical 
castration. They are used early and late in the course of the disease. GnRH 
agonists bind to the GnRH receptors on pituitary gonadotropin-producing cells, 
which cause a temporary release of LH and FSH. However, after a few weeks 
desensitation occurs, meaning that the pituitary cells internalize the GnRH 
receptor reducing the synthesis of LH and FSH and eventually testosterone to 
castrate levels or below the castrate threshold (50 ng/dL) (112). Formulations 
include: leuprolide, triptorelin, goserelin, histrelin. Common side effects of 
GnRH agonists are hot ﬂashes, decreased libido, anemia, gynecomastia, fatigue, 
headache, depression, changes in skin texture, and bone mineral 




cardiovascular diseases incidence and mortality, diabetes, and lipid profile 
alterations which will be described in chapter IV (109). 
 GnRH antagonists: These drugs bind competitively to GnRH receptors, leading 
to an immediate inhibition of LH, FSH and testosterone synthesis. As a 
consequence no flare effect is observed. Furthermore, an extended follow-up 
study has been published suggesting better progression-free survival compared 
with monthly leuprolide (114). Moreover, in a study looking at cardiovascular 
events in men receiving either GnRH agonists or antagonists, it was found that 
antagonists halve the number of cardiac events experienced by men with 
preexisting cardiovascular disease during the first year of ADT (115). 
 Antiandrogens: These competitively bind to the androgen receptor and inhibit 
its interaction with testosterone and dihydrotestosterone. There are two types 
of antiandrogens: the steroid antiandrogens and the non-steroidal 
antiandrogens (NSAA). The most used steroid antiandrogen is cyproterone 
acetate. These types of antiandrogens are weak partial agonists and 
competitive inhibitors of the androgen receptor. They also have progestational 
agonist actions that, by a negative feedback effect, lower LH secretion. 
Subsequently LH stimulated testosterone production decreases leading to the 
loss of libido, decreased sexual potency and low testosterone levels.  
The NSAA also block androgen receptor testosterone binding in the central 
nervous system interrupting the negative feedback of testosterone on 
gonadotropin secretion. Therefore, testosterone levels increase presenting less 
sexual side effects than the steroid antiandrogens. However, testosterone 
excess is converted into estrogens by aromatases and as a consequence 
gynecomastia and breast tenderness may occur. Common formulations are 
flutamide, nilutamide and bicalutamide.  
Antiandrogens are generally used in combination with a GnRH agonist, 
however in some countries they are used as monotherapy (116).  
 Other hormones: Currently there is one medication that combines an alkylating 
agent to estradiol: Estramustine. Alkylating agents are compounds that 
introduce DNA changes (alkyl groups) that halt cell division and are used as 




Estrogens were the first drugs used to block the synthesis of LH and thus 
androgen concentrations in blood inducing tumour regression. However, due 
to adverse effects and the discovery of new drugs, their application as single 
therapy agents was discontinued (118). Nonetheless, in the last decades it has 
been observed that the main side effects of estrogens were due to liver 
metabolism of the drug and it can be avoided by parenteral administration (i.e. 
transdermal patches). As a result, estrogens are currently being studied in 
comparison to GnRH agonists in a clinical trial with primary outcomes overall 
survival and progression free survival (119). 
 
2.2.5.4. Other prostate cancer drugs 
For metastatic and castrate resistant prostate cancer (CRPC) several other drug 
combinations are used. Antimicrotubule drugs such as docetaxel and cabazitaxel have 
demonstrated improvements in overall survival in patients with very advanced disease. 
Another drug used for CRPC is Abiraterone acetate: a first-in-class inhibitor of 
cytochrome P-450c17, a critical enzyme in extragonadal and testicular androgen 
synthesis (120).  Furthemore, Abiraterone has been found to reduce the risk of death 
when combined with ADT compared to ADT alone in metastatic hormone sensitive 
prostate cancer (121). 
 
Enzalutamide is an androgen-receptor inhibitor that inhibits androgen-receptor 
translocation to the cell nucleus, recruitment of androgen-receptor cofactors, and 
androgen-receptor binding to DNA (122).These drugs can be used in combination with 
corticosteroids (prednisone, hydrocortisone, dexamethasone), which are used as 
palliative medication due to their anti-inflammatory and immune suppressive effects. 
Currently, in the Phase II/II Systemic Therapy in Advancing or Metastatic Prostate 
Cancer: Evaluation of Drug Efficacy (STAMPEDE): A Multi-Stage Multi-Arm Randomised 
Controlled Trial, several combinations of these drugs are being evaluated in the 
treatment of advanced or metastatic prostate cancer with overall survival as the 
primary outcome. Some of the treatment arms are still recruiting and the reference 






Monoclonal antibodies (denosumab) are being used to prevent skeletal related injuries 
due to bone metastasis. This antibody binds to the receptor activator of nuclear factor 
kappa B ligand (RANKL), which acts as the primary signal to promote bone removal 
(15). Sipuleucel-T is a vaccine containing activated antigen-presenting cells from the 








2.3. Disease and treatment related clinical outcomes for men with prostate 
cancer 
 
The following section of this chapter provides a background for the four projects 
conducted as part of this PhD – and thus specifically focuses on clinical outcomes for 
men already diagnosed with prostate cancer. Further details on the rationale for each 
project are also provided in the following chapters. 
 
2.3.1. Serum biomarkers and secondly diagnosed primary tumours in men with 
prostate cancer 
One of the biggest fears cancer survivors face is the diagnosis of a new cancer. In the 
United States of America Surveillance, Epidemiology and End Results program (SEER) 
second primary tumours (SPTs) or subsequent cancers represent 16% of incident 
cancers (125). 
 
Several studies have specifically focused on prostate cancer and the risk of SPTs (126-
128). For instance, it has been shown in a cohort of American men, that those men 
with prostate cancer who underwent orchiectomy had a 40% higher risk of developing 
colorectal cancer (129). Moreover, it has been reported that men with prostate cancer 
show a higher risk of developing bladder cancer, although this finding may be due to 
detection bias (130). A study performed using a Swiss cohort concluded that the 
overall risk of SPTs is higher in prostate cancer men, and this risk was even higher after 
10 years of receiving radiotherapy (131).   
 
Smoking, obesity and insulin resistance are some of the well-known risk factors for the 
development of first primary tumours (132-137). Nonetheless, whether these risk 
factors can increase the risk of developing SPTs is less clear. Evidence indicates that 
SPTs may be the result of genetic and hormonal risk factors (138-140), as well as late 
effects of chemo and radiotherapy (125, 141). In the context of prostate cancer, it has 
been suggested that the IGF-1 could play a role in the development of secondary 




(142, 143).  Even though epidemiological evidence observes an association between 
prostate cancer and SPTs, whether there are convergent biological pathways remains 
unknown. Thus, it is important to further investigate aetiological influences that 
increase risk of SPTs, so that we can better define high-risk groups for targeted 
preventive and interventional clinical strategies (144). 
 
As part of this PhD project I aimed to investigate how serum biomarkers of the 
glucose, liver and lipid metabolism measured before prostate cancer diagnosis are 
associated with patterns of SPTs. For instance, there has been growing evidence for a 
role of the glucose and lipid metabolism in tumour development. ROS are examples of 
mechanisms through which these metabolic abnormalities might be connected to 
cancer risk (145). Diabetes and its treatment, as well as serum levels of glucose, are 
the most commonly used markers of the glucose metabolism in the context of cancer 
(146). Another possible link between oxidative stress and cancer development is 
suggested in recently published epidemiological studies that showed a link between 
gamma-glutamyltransferase (GGT), a metabolic marker of liver dysfunction, and cancer 
risk (147). GGT is a central enzyme of the metabolism of glutathione, which plays an 
important role in maintaining tissue oxidant/antioxidant balance, cellular defence, 
proliferation, and death (147). Increased levels of GGT appear to reflect high levels of 
glutathione turnover in response to intracellular oxidative stress. The persistent 
production of ROS as a result of increased GGT expression in tumour cells may 
contribute to genetic instability and to tumour progression (148). Also, inflammatory 
markers are suggested to be linked to cancer development through increased 
oxidative stress (149), which may potentially link dyslipidemia to carcinogenesis. 
Dyslipidemia is associated with a state of low-grade chronic inflammation, infiltrating 
macrophages within adipose tissue, and elevated concentrations of pro-inflammatory 
molecules (150). In addition, there has been consistent evidence of lipid oxidation (of 
low-density lipoprotein phospholipids) playing a role in many metabolic disorders, 





Hence, the first project of this PhD project (Chapter III) aimed to increase our 
understanding of possible indicators for cancer prevention in men with prostate 
cancer. 
 
2.3.2. Radiotherapy and the risk of thromboembolic disease 
Thromboembolic disease (TED) is a condition in which a thrombus either arises 
spontaneously or is caused by clinical conditions as listed below. Venous thrombi 
usually form in the valve pockets of the legs veins, where there is a low blood flow and 
are mainly made of fibrin, red blood cells and platelets. Deep venous thrombosis (DVT) 
and pulmonary embolism (PE) are TED manifestations (151). 
 
In 1884, Rudolph Virchow proposed that thrombosis was the result of the presentation 
of one or more of the following conditions: vascular endothelial damage, stasis of 
blood flow and hypercoagulability of blood. Through time, it was found that these 
conditions were present in cancer, prolonged periods of immobilisation, major 
surgery, hip fracture, spinal cord injury, prior thromboembolic events, hereditary 
coagulopathies amongst others as listed in figure 10 (152). In the last decades, 
metabolic syndrome has also been found to be a risk factor for TED, as several of its 





Figure 10 Virchow’s triad of risk factors for venous thromboembolism (adapted from (156)) 
 
 
Even though RT has been associated with an increased risk of TED for other cancers 
(i.e. lung, uterus), no studies have been published on this association for prostate 
cancer (157, 158).  It is thus not known whether RT is a risk factor for TED or whether 
TED is a side effect of RT. However, it is of interest to investigate this link, as there are 
biological findings that suggest a possible association. 
 
It has, for instance, been reported that RT can induce structural changes in arteries in 
patients who have previously undergone RT for lymphoma, breast cancer, and head 
and neck cancer (159). Furthermore, according to experimental studies, RT can 
activate nuclear factors that promote inflammation status in the vascular wall cells, a 
key step in in the coagulation cascade (160).  
 
Based on the above, the aim of the second project in this PhD (Chapter IV) was to 





2.3.3. Drugs for metabolic conditions and prostate cancer death in men on 
GnRH agonists 
The risk of type 2 diabetes, as well as other components of the metabolic syndrome 
(MetS), following initiation ADT for prostate cancer, has been studied and analysed in 
several cohorts. Overall, it is thought that ADT is associated with an increased risk of 
diabetes as well as MetS (161). Several definitions have been proposed for MetS. In 
general, the following symptoms are involved: central obesity, raised triglycerides or 
specific treatment for this lipid abnormality, reduced high-density lipoprotein (HDL) 
cholesterol or specific treatment for this lipid abnormality, raised blood pressure or 
treatment of previously diagnosed hypertension, or raised fasting plasma glucose 
(162). 
 
However, less attention has been given to how being diagnosed and getting treatment 
for MetS components before prostate cancer diagnosis may also affect ADT response 
in terms of prostate cancer survival. Only two recent studies have investigated this 
scenario, with one suggesting that having metabolic syndrome at time of ADT initiation 
may shorten time to castrate resistant prostate cancer and overall survival (163).  The 
other study found no statistically significant associations between baseline metabolic 
syndrome or its components and risk of prostate cancer specific death (164).  
 
GnRH agonists aim to deprive prostate cancer cells from the growth stimuli provided 
by testosterone. However, it has been established that not all prostate cancer cells 
need testosterone to grow and survive; moreover those known as castrate resistant 
cancers are more aggressive and progress more rapidly. Metabolic syndrome and its 
individual components are associated with low circulating testosterone levels (165). 
For instance, in the EPIC study men with diabetes had 26% lower risk of prostate 
cancer and lower levels of circulating concentrations of androstenedione, total 
testosterone and insulin-like growth factor binding protein-three than those who did 
not have diabetes (166). This could thus potentially explain why men who present with 





To further evaluate how metabolic components and their related drugs have an impact 
on prostate cancer death, the third study of this PhD project aimed to evaluate how a 
variety of treated metabolic syndrome components diagnosed before prostate cancer 
diagnosis are associated with prostate cancer death in men who started on primary 
ADT. 
 
2.3.4. Anti-androgens versus GnRH agonists in relation to prostate cancer 
death 
In Europe, both GnRH agonists and AAs are currently approved as ADT monotherapies 
for high-risk locally advanced prostate cancer (167). However, the European Urology 
Association (EUA) does not recommend the use of AA as monotherapy based on the 
results of a 2014 Cochrane systematic review and meta-analysis (17). Nonetheless, in 
the Cochrane review it was shown in the subgroup analysis of non-metastatic disease 
that there was no significant difference between AA and castration in terms of overall 
survival (168). Two previous RCTs looking at AA vs. GnRH agonists and overall survival 
and prostate cancer specific survival had similar results to the subgroup analysis of the 
Cochrane review (169, 170).  Yet, more recently it has been accepted that “real-world” 
data is more likely to better reflect clinical practice experiences rather than RCTs in 
which patients are highly selected. 
 
Therefore, considering that GnRH agonists are associated with a number of negative 
metabolic effects including bone loss with increased risk of fractures, increased risk of 
cardiovascular disease, diabetes mellitus type 2 and possibly dementia (171-174) and 
in order to assess the external validity of these early RCTs, I performed a nationwide, 
population-based observational study on AA monotherapy versus GnRH agonists and 






3. Chapter III: Disease-related outcomes 
3.1. Serum biomarkers and secondly diagnosed primary tumours in men with 
prostate cancer- results from the AMORIS database  
The findings of this study were presented as an abstract at the NCRI Conference in 2015 
(Appendix I). The manuscript is currently under review with BMC Cancer. 
 
3.1.1. Rationale 
As already mentioned, due to advances in detection and treatment, the prevalence of 
prostate cancer is increasing (125). These trends translate into more men living longer 
with prostate cancer diagnosis and consequently being at risk of getting diagnosed 
with a second primary tumour. Travis et al. suggested grouping of second primary 
malignancies based on leading etiological causes: treatment-related, syndromic, and 
those due to shared etiologic factors (125). Most studies to date have focused on 
primary cancer treatment related second primary malignancies (175, 176) and little is 
known about other causes of these tumours. However, it was recently suggested that 
radiotherapy is only responsible for <10% of second primary malignancies, implying a 
larger role for lifestyle, genetic or biochemical related factors in their development 
(177). There are several definitions for second primary malignancies, and although 
most definitions contemplate the fact that it cannot be a metastasis of a first primary 
tumour, there is an implicit notion that second primary malignancies must have 
started developing after the first primaries. This implicit notion may be accurate for 
those second malignancies in which the lag time between treatment of the first 
primary tumour or long-term exposure to certain factors has taken place before the 
occurrence of the second primary malignancy. However, for those tumours diagnosed 
within a relatively short period of time after diagnosis of first primary malignancies, 
these factors are less likely to play a role in the development of a second primary 
malignancy. Here, I refer to second primary tumours as those primary tumours (non-
metastatic) of any organ/tissue diagnosed after diagnosis of prostate cancer. “Second” 
does not refer to when the tumour started developing, it refers to when it was 




concept, below I will refer to these tumours as “secondly diagnosed primary tumours” 
(SDPTs). 
 
Abnormal metabolism in cancer cells has been well studied and continues to be of high 
interest as a potential target for drug development (178). It is therefore of interest to 
investigate serum biomarkers measured before a first primary cancer as these could 
activate mechanisms leading to other cancer development or be a consequence of 
common alterations that will lead to a second cancer (179).  
 
Studies based on the Swedish AMORIS study have reported that the interplay between 
serum lipids, glucose and gamma-glutamyl transferase (GGT) increases the risk of 
prostate cancer (180-182). Since cancer development following exposure to risk 
factors may take several decades (183), we hypothesized that these elevated serum 
levels of glucose, total cholesterol, triglycerides, fructosamine and GGT measured 
before prostate cancer diagnosis may also be associated with development of SDPTs – 
either because these biomarkers activate a shared carcinogenic mechanism or because 
they are the consequence of a common underlying alteration (179, 184, 185) . I 
therefore conducted a hypothesis-generating study to evaluate how serum biomarkers 
of common metabolisms are associated with development of prostate cancer and 
subsequent other cancers.   
 
3.1.2. Methods 
3.1.2.1. Data source: AMORIS 
The AMORIS (Apolipoprotein-related MOrtality RISk) cohort has been described in 
detail elsewhere (52, 186-188). During the period 1985–96, the Central Automation 
Laboratory (CALAB), Stockholm, Sweden was a leading centre for analyses of blood and 
urine samples from health screenings and primary health care in Sweden. The AMORIS 
cohort was initiated by Ingmar Jungner, one of the founders of CALAB, and Göran 
Walldius, the medical advisor. This AMORIS cohort was originally set up to test if levels 
of apolipoprotein (apo) B (atherogenic) and apoA-I (atheroprotective) were more 




especially low-density lipoprotein (LDL)-cholesterol. In 2012, Ingmar Jungner donated 
the CALAB database to the Karolinska Institutet, Stockholm, Sweden, for research 
purposes in general and in the short term to support the on-going research project 
‘Epidemiologic studies of metabolic factors and inflammation in relation to chronic 
diseases’. This database includes 812,073 Swedish men and women with blood and/or 
urine samples. Individuals recruited were either healthy and having laboratory testing 
as part of a general check-up or outpatients referred for laboratory testing. None of 
the participants were inpatients at the time of sampling (189, 190). The CALAB 
database was further updated in 2012–14 in connection with the above-mentioned 
research project by record linkages to 24 Swedish national health registers, quality of 
care registers and research cohorts. This included the Swedish National Cancer 
Register, the Hospital Discharge Register, the Cause of Death Register, the Swedish 
Prostate Cancer Register, the consecutive Swedish Censuses during 1970–1990, and 
the National Register of Emigration using the Swedish 10-digit personal identity 
number (these registers are further described in chapter IV) (191-193) (Figure 11). 
Previous studies based on the AMORIS cohort focusing on prostate cancer can be 





Table 7. AMORIS studies focused on prostate cancer 
Author  Cohort Biomarkers Results 
Van Hemelrijck et 
al.(194) 
69,735 LDL, HDL, ApoB, 
ApoA-I 
Low HDL and ApoA-I and increased lipid 
ratios are associated with higher risk of 
prostate cancer 
Van Hemelrijck et 
al..(195) 
196,022 Calcium, Albumin Weak negative association between 
Calcium and prostate cancer risk likely due 
competing risks 







No association between inflammatory 
markers and prostate cancer 
Van Hemelrijck et 
al.(187) 
200,660 TG,TC, Glucose Negative association between glucose and 
prostate cancer risk for the second, third, 
and fourth quartiles compared with the 
first. Positive association between 
hypertriglyceridemia and prostate cancer 
risk, in combination with high glucose 
levels. No association was found for 
hypercholesterolemia. 
LDL: Low density lipoprotein, HDL: High-density lipoprotein, ApoA: Apolipoprotein A, ApoB: 










3.1.2.2.  Study population 
From the AMORIS cohort, I selected all men diagnosed with prostate cancer that had 
at least one of the five biomarkers of interest (glucose, total cholesterol, triglycerides, 
fructosamine and GGT) measured before prostate cancer diagnosis. To obtain 
information on stage and treatment of prostate cancer, I used a linkage of the AMORIS 
cohort with the National Prostate Cancer Register (NPCR), resulting in a total of 14,021 
prostate cancer cases (54). As carcinogenesis may initiate several years before 
diagnosis, I divided the time between blood measurement and prostate cancer 
diagnosis into five periods to exhibit this potential lag time: 0-5, 5-10, 10-15, 15-20 
years and more than 20 years before prostate cancer diagnosis. For the current study, I 
focused on those measurements taken 10-15 and 15-20 years prior to prostate cancer 
diagnosis (n= 10,791 cases) (Figure 12). Excluding the most recent periods limits the 
potential effects of reverse causation. Moreover, prostate cancer is known to have a 
long natural history (196). If men had more than one measurement taken within the 
period studied, the measurement closest to the mid-point of the interval was selected. 
Follow-up started at the time of prostate cancer diagnosis and ended at time of 
occurrence of a SDPT, emigration, death or end of the study (December 31st 2011), 
whichever came first.  
 
Information on educational level was retrieved from the Population and Housing 
Census. Using information from the National Patient Register, I calculated a baseline 
Charlson comorbidity index (CCI), which includes 19 diseases, with each disease 
category assigned a weight. The sum of an individual’s weights was used to create a 
score, resulting in four comorbidity levels ranging from no comorbidity to severe 
comorbidity (0, 1, 2, and ≥3) (197). 
 
3.1.2.3.  Exposure variables 
The main exposure variables of interest were the above-mentioned five biomarkers. I 
used both quartiles and medical cut-offs for the analyses. Medical cut-offs for glucose 
(6.11 mmol/L), total cholesterol (6.5 mmol/L) and triglycerides (1.71 mmol/L) were 
based on the National Cholesterol Education Program guidelines (198). Fructosamine 




defined based on the laboratory cut-offs used by CALAB which have also been applied 
in other recent studies (2.5 mmol/L and 36 IU/L respectively) (181, 199).  
Figure 12 Selection of men with Prostate cancer from the AMORIS cohort to study the association between 
metabolism markers and risk of Second Primary Tumours 
 
N=21,303 
Men with Prostate 
cancer as registered in 
the Swedish National 
Cancer Register. 
N=17,597 
Men with Prostate 
cancer, as registered in 
the Swedish National 
Cancer Register and 
AMORIS who had a least 
one of the biomarkers of 
interest measured 





data (as of 1996). 
N=14,021 
Men with Prostate cancer who 
have at least one of the 
biomarkers of interest 
measured before Prostate 
cancer diagnosis and have 
information available on 
treatment and Prostate cancer 
stage. 
N=10,791 
Men with Prostate cancer who 
have at least one of the 
biomarkers of interest 
measured between 10 to 20 





Although these biomarker measurements were part of regular health check-up and 
missing data could therefore be considered missing at random, I used the most general 
approach to the problem of missing data: multiple imputation. More specifically, I 
applied multivariate imputation using chained equations (MICE), also known as 
imputation using fully conditional specifications (200). The MICE method imputes 
multiple variables sequentially using univariate fully conditional specifications.  
 
Glucose was measured enzymatically with a glucoseoxidase/peroxidase method. Total 
cholesterol was determined with the cholesterol oxidase/peroxidase assay and 
triglycerides with the glycerol phosphate oxidase/peroxidase assay (191, 192). GGT 
levels measurement was performed with an enzymatic colorimetric test using L-c-
glutamyl-3-carboxy-4-nitroanilide as donor substrate at a temperature of 370C, which 
is the reference method recommended by the International Federation of Clinical 
Chemistry and Laboratory Medicine (201). Fructosamine was measured by the 
Nitroblue Teterazolium colorimetric technique based on the reducing ability of 
fructosamine in an alkaline solution (202). 
 
All methods were fully automated with automatic calibration and performed at one 
and the same accredited laboratory (CALAB) (191). 
 
3.1.2.4. Outcome definition 
The main outcome of interest was the occurrence of cancer diagnosed after prostate 
cancer diagnosis. SDPTs were defined as any non-benign and non-metastatic tumour, 
and grouped according to the International Classification of Diseases 7th revision  
(ICD7) codes (203) which are the codes used to enter the data in the register. Based on 
previous evidence (204), rectal SDPTs were grouped together with genitourinary 
tumours for anatomic reasons to account for possible effects of radiotherapy and 





3.1.2.5. Statistical Analysis 
Baseline cohort characteristics were compared using descriptive statistics (Student’s t-
test, Wilcoxon Rank Sum test, and Chi squared test). Multivariate Cox proportional 
hazards regression analysis with age as a timescale was used to determine hazard 
ratios (HR) and 95% confidence intervals (95% CI) of risk of SDPTs. I adjusted for the 
remaining biomarkers, fasting status, prostate cancer treatment, CCI at prostate 
cancer diagnosis, diabetes mellitus at prostate cancer diagnosis, time between blood 
test and prostate cancer diagnosis and education. Even though information on grade 
and treatment were both available, I only adjusted for cancer treatment to avoid 
collinearity – treatment is a well-accepted indication of disease severity (205). 
 
Furthermore, I ran an analysis according to the type of SDPT for those cancer groups 
that had at least 60 events leaving out other types of cancers (i.e. haematological). The 
assumption of proportionality of the Cox model covariates was tested by plotting 
Schoenfeld residuals on several of the imputed datasets (206). To address the 
potential effects of prostate cancer treatment I performed both a stratified analysis as 
well as an additional adjustment for prostate cancer treatment.  
 
The study complied with the Declaration of Helsinki and was approved by the Ethics 
Review Board of the Karolinska Institutet (Dnr 2010/1:7). 
 
Statistical Analysis Software (SAS) release 9.4 (SAS Institute, Cary, NC) was used for 
data management; Stata Statistical Software: Release 14 (College Station, TX: 
StataCorp LP) was used for imputation and data analysis. 
 
3.1.3. Results 
Study population baseline characteristics for prostate cancer cases with and without a 
SDPT are described in Table 7. A total of 811 SDPTs (7.5 %) were diagnosed during a 
mean follow-up time of 4.98 (SD: 3.36) years.  
 
Multivariate analysis including all biomarkers studied showed a higher risk of SDPTs for 




triglycerides (HR: 1.37, 95%CI: 1.17-1.60), total cholesterol (HR: 1.22, 95%CI: 1.04-1.42) 
and GGT (HR: 1.32, 95%CI: 1.02-1.71), as compared to the normal levels (Table 9). 
When looking at quartiles, only those in the 4th quartile of triglycerides were at higher 
risk of SDPTs, as compared to the first quartile. A weaker positive association with risk 
of developing a SDPT was also observed for those in the 4th quartiles of total 
cholesterol and GGT, as compared to the first quartile (table 9). 
 
Cancer treatment stratified analysis did not substantially change these associations 
(table 10). 
 
The risk of SDPTs of digestive organs, peritoneum, genitourinary and rectum was also 
higher for those with elevated blood levels of triglycerides. Furthermore, high levels of 
GGT were associated with SDPTs of the respiratory system. Total cholesterol levels 







Figure 13 Hazard ratios and 95%CI (X-axis) for risk of specific types of SDPTS by levels of total cholesterol, 
glucose, triglycerides, and GGT based on their medical cut-off* 
 
*6.5 mmol/L, 6.11 mmol/L, 1.71 mmol/L and 36 IU/L respectively. All models were adjusted for Education, diabetes mellitus at 
Prostate cancer diagnosis, age, CCI, Fasting Status, time between date of blood test and Prostate cancer diagnosis date, Prostate 














Age     
Mean (SD) 69.83 (7.07)  68.06 (7.89)  
<63 133 16.40 2693 26.98 
63-67.99 191 23.55 2417 24.21 
68-73.99 253 31.20 2542 25.46 
>74 234 28.85 2331 23.35 
Education     
High 226 27.87 3132 31.37 
Middle 352 43.40 4088 40.95 
Low/no 222 27.37 2619 26.23 
Missing data 11 1.36 144 1.44 
Glucose (mmol/L)     
Mean (SD) 5.10  (1.28)  5.09 (1.19)  
>6.11 54 6.66 661 6.62 
<6.11 724 89.27 8672 86.87 
Missing data 33 4.07 650 6.51 
Triglycerides (mmol/L)     
Mean (SD) 1.64 (1.26)  1.53 (1.06)  
>1.71 270 33.29 2751 27.56 
<1.71 530 65.35 7028 70.40 
Missing data 11 1.36 204 2.04 
Cholesterol (mmol/L)     
Mean (SD) 6 (1.02)  5.91 (1.05)  
>6.5 275 33.91 2797 28.02 
<6.5 526 64.86 7016 70.28 
Missing data 10 1.23 170 1.70 
Fructosamine (mmol/L)     
Mean (SD) 2.11 (0.32)  2.11 (0.26)  
>2.5 31 3.82 296 2.97 
<2.5 575 70.90 7307 73.19 
Missing data 205 25.28 2380 23.84 
GGT (IU/L)     
Mean (SD) 36.98 (97.36)  32.30 (35.29)  
>36 69 8.51 701 7.02 
<36 688 84.83 8424 84.38 
Missing data 54 6.66 858 8.59 
CCI at PCa diagnosis     
0 606 74.72 7705 77.18 
1 131 16.15 1451 14.53 
2 45 5.55 466 4.67 
3+ 29 3.58 361 3.62 
Diabetes at PCa diagnosis     
Yes 42 5.18 418 4.19 




FUT 3.77 (2.83)  5.28 (3.22)  
Treatment     
RT 101 12.45 1040 10.42 
RP 175 21.58 2936 29.41 
HT 206 25.40 2211 22.15 
DT (AS WW) 231 28.48 2332 23.36 
Unspecified 55 6.78 823 8.24 
Missing data 43 5.30 641 6.42 
Stage group     
Low risk 205 25.28 3140 31.45 
Intermediate risk 251 30.95 2791 27.96 
High risk 225 27.74 2220 22.24 
Regionally metastatic 41 5.06 567 5.68 
Distant metastases 59 7.27 928 9.30 
Missing data 30 3.70 336 3.37 
Abbreviations: GGT: gamma glutamyl transferase, Prostate cancer: prostate cancer, SDPTs: secondly diagnosed primary tumours,  
CCI: Charlson comorbidity index, FUT: follow up time; RT: Radiotherapy, RP: radical prostatectomy, HT: hormonal treatment, 





Table 9. Univariate and multivariate Cox proportional hazards regression analysis for risk of SDPTs by levels of 
serum biomarkers (Glucose, triglycerides, total cholesterol, GGT, and fructosamine). 
   Univariate Multivariate p-
value/tre
nd 
  Variables HR 95%CI HR 95%CI 
Clinical 
cut-offs 
Glucose (6.11 mmol/L) 1.11 0.84-1.46 0.87 0.64-1.19 0.42 
TG (1.71 mmol/L) 1.37 1.18-1.58 1.37 1.17-1.6 <0.001 
TC (6.5 mmol/L) 1.33 1.15-1.54 1.22 1.04-1.42 0.01 
GGT (36 IU/L) 1.37 1.07-1.76 1.32 1.02-1.71 0.02 
FAMN (2.5 mmol/L) 1.27 0.88-1.82 0.91 0.59-1.39 0.64 
Quartiles 
Gluc-q1(<4.6mmol/L) 1 ref 1 ref 
0.56 
Gluc-q2 (4.6-5mmol/L) 1.29 1.06-1.57 1.25 1.03-1.52 
Gluc-q3 (5-5.4mmol/L) 1.09 0.89-1.33 1.01 0.83-1.24 
Gluc-q4(>5.4mmol/L) 1.15 0.95-1.39 0.98 0.8-1.19 
TC-q1(<5.2mmol/L) 1 ref 1 ref 
0.09 
TC-q2(5.2-5.8 mmol/L) 1.1 0.88-1.36 1.05 0.84-1.3 
TC-q3(5.8-6.6 mmol/L) 1.06 0.87-1.3 0.98 0.8-1.49 
TC-q4(>6.6 mmol/L ) 1.38 1.14-1.67 1.21 0.99-1.49 
Tg-q1 (<0.9 mmol/L) 1 ref 1 ref 
0.004 
Tg-q2 (0.9-1.3 mmol/L) 0.95 0.76-1.18 0.94 0.75-1.17 
Tg-q3(1.3-1.9 mmol/L) 1.11 0.91-1.34 1.08 0.88-1.31 
Tg-q4(>1.9 mmol/L) 1.35 1.12-1.62 1.32 1.08-1.61 
Ggt-q1(<16.79 IU/L) 1 ref 1 ref 
0.27 
Ggt-q2(16.79-23.39 IU/L) 1.07 0.87-1.32 1.05 0.86-1.29 
Ggt-q3 (23.39-35.99 IU/L) 1.05 0.86-1.29 0.99 0.8-1.22 
Ggt-q4 (>35.99) 1.24 1.01-1.52 1.15 0.93-1.42 
Famn-q1 (<2 mmol/L) 1 ref 1 ref 
0.26 
Famn-q2 (2-2.11 mmol/L) 0.88 0.69-1.11 0.84 0.66-1.07 
Famn-q3 (2.11-2.25 
mmol/L) 
0.97 0.79-1.21 0.91 0.73-1.14 
Famn-q4 (>2.25 mmol/L) 0.99 0.8-1.24 0.85 0.67-1.07 
Abbreviations: Gluc: glucose, TC: total cholesterol, TG: triglycerides, GGT: gamma glutamyl transferase, 
 FAMN: fructosamine, Prostate cancer: prostate cancer, SDPTs: secondly diagnosed primary tumours, HR: Hazard ratios, CI: Confidence intervals 
**Adjusted for: Education, diabetes mellitus at Prostate cancer diagnosis, age, CCI,  Fasting Status, time between date of blood test and Prostate cancer 




Table 10. Treatment stratified analysis according to biomarkers blood levels clinical cut offs and quartiles 
   RT RP HT DT 
 Variables HR 95% CI  HR 95% CI  HR 95% CI HR 95% CI  
Clinical cut 
offs 
Glucose (6.11 mmol/L) 0,64 (0.24-1.72) 1,16 (0.56-2.41) 1,06 (0.6-1.88) 1,62 (1.01-2.6) 
TG (1.71 mmol/L) 1,46 (0.91-2.33) 1,14 (0.78-1.66) 1,02 (0.71-1.46) 1,64 (1.2-2.25) 
TC (6.5 mmol/L) 1,71 (1.08-2.7) 1,31 (0.90-1.91) 1,31 (0.94-1.83) 1,17 (0.86-1.6) 
GGT (36 IU/L) 1,20 (0.64-2.27) 1,70 (1.05-2.75) 1,32 (0.81-2.15) 0,99 (0.62-1.57) 
FAMN (2.5 mmol/L) 1,27 (0.47-3.4) 0,75 (0.29-1.96) 0,68 (2.73-1.69) 0,57 (0.23-1.42) 
Quartiles 
Gluc-q1(<4.6mmol/L) ref ref ref ref ref ref ref ref 
Gluc-q2 (4.6-5mmol/L) 1,38 (0.76-2.49) 1,59 (1.02-2.48) 1,10 (0.72-1.69) 0,88 (0.58-1.33) 
Gluc-q3 (5-5.4mmol/L) 1,09 (0.58-2.04) 1,08 (0.66-1.75) 0,81 (0.52-1.27) 0,99 (0.68-1.46) 
Gluc-q4(>5.4mmol/L) 1,27 (0.69-2.33) 1,64 (1.03-2.61) 1,15 (0.76-1.74) 1,05 (0.72-1.53) 
TC-q1(<5.2mmol/L) ref ref ref ref ref ref ref ref 
TC-q2(5.2-5.8 mmol/L) 1,01 (0.48-2.12) 0,95 (0.57-1.59) 0,82 (0.53-1.28) 0,84 (0.55-1.3) 
TC-q3(5.8-6.6 mmol/L) 1,42 (0.74-2.71) 1,12 (0.7-1.79) 0,52 (0.33-0.81) 1,07 (0.74-1.55) 
TC-q4(>6.6 mmol/L ) 1,85 (0.96-3.58) 1,44 (0.89-2.32) 1,07 (0.71-1.61) 1,07 (0.71-1.6) 
Tg-q1 (<0.9 mmol/L) ref ref ref ref ref ref ref ref 
Tg-q2 (0.9-1.3 mmol/L) 0,89 (0.44-1.8) 1,01 (0.62-1.66) 0,97 (0.61-1.53) 0,86 (0.55-1.36) 
Tg-q3(1.3-1.9 mmol/L) 0,72 (0.39-1.36) 0,98 (0.61-1.55) 1,19 (0.78-1.81) 1,08 (0.73-1.59) 
Tg-q4(>1.9 mmol/L) 1,17 (0.65-2.2) 1,16 (0.73-1.85) 0,99 (0.62-1.58) 1,76 (1.19-2.61) 
Ggt-q1(<16.79 IU/L) ref ref ref ref ref ref ref ref 
Ggt-q2(16.79-23.39 IU/L) 0,85 (0.43-1.69) 1,44 (0.91-2.26) 1,05 (0.68-1.62) 0,93 (0.64-1.36) 
Ggt-q3 (23.39-35.99 IU/L) 1,55 (0.85-2.84) 1,02 (0.62-1.68) 1,18 (0.77-1.8) 0,70 (0.47-1.06) 
Ggt-q4 (>35.99) 1,36 (0.74-2.49) 1,24 (0.77-2.02) 0,96 (0.61-1.52) 0,96 (0.64-1.43) 
Famn-q1 (<2 mmol/L) ref ref ref ref ref ref ref ref 
Famn-q2 (2-2.11 mmol/L) 0,84 (0.45-1.56) 0,81 (0.52-1.27) 0,86 (0.55-1.33) 0,88 (0.59-1.29) 
Famn-q3 (2.11-2.25 mmol/L) 0,95 (0.51-1.74) 0,59 (0.37-0.94) 1,02 (0.67-1.53) 0,85 (0.58-1.25) 
Famn-q4 (>2.25 mmol/L) 0,80 (0.42-1.49) 0,56 (0.34-0.90) 0,80 (0.5-1.27) 0,80 (0.53-1.22) 
Abbreviations: Gluc: glucose, TC: total cholesterol, TG: triglycerides, GGT: gamma glutamyl transferase, FAMN: fructosamine, RT: radiotherapy, RP: radical prostatectomy, HT: hormonal treatment, DT: deferred treatment, 





To the best of my knowledge, this is the first study investigating an association 
between serum markers of lipids, glucose and GGT and development of SDPTs in men 
with prostate cancer. High levels of cholesterol, triglycerides and GGT measured on 
average 16 years prior to prostate cancer diagnosis were associated with an increased 
risk of developing a SDPT. When looking at specific types of SDPTs, I found an 
increased risk of SDPTs of digestive organs, peritoneum, genitourinary and rectum for 
those with elevated levels of triglycerides. High levels of GGT were also associated with 
an increased risk of SDPTs of the respiratory system. 
 
Carcinogenesis is a complex process that can require several components to act/occur 
before irreversible disease develops. This concept implies the temporality of the 
component causes, meaning that the factors involved in the development of the 
disease do not necessarily happen at the same time. The present paper illustrates 
these well-described characteristics of the sufficient-cause model (25). By analysing 
how biomarkers of different metabolism measured before PCa diagnosis are 
associated to the occurrence of a secondly diagnosed primary tumour-while 
accounting for all possible confounders given the available data- we have been able to 
establish a possible component cause for these tumours. Which other components 
need to occur (either as cause or prevention i.e. taking any medication that may 
reduce the risk of cancer) and when escapes the scope of this study and further 
research to establish other component causes is needed. Whether the strength of the 
association would be wakened by including in the model other potential component 
causes that we haven’t been able to account for would not disregard the potential 
etiological significance of this study results.  
 
My findings for SDPTs were consistent with our and other previously published 
findings for these biomarkers and primary prostate cancer (181, 184, 207, 208). 
Interestingly, results from a recent nested case-control study on the association 
between circulating fatty acids and prostate cancer showed that those who had been 
diagnosed 10 or more years after blood collection had stronger associations than those 




hypothesis that metabolic factors may play a role several years before disease 
occurrence and detection (209). 
 
Below I describe my findings in the context of other epidemiological studies as well as 
the hallmarks of cancer (183, 210).  
 
Lipid metabolism  
Elevated levels of cholesterol and triglycerides are associated with a higher risk of 
prostate cancer, gastrointestinal and renal cancer (211, 212). In the AMORIS study 
these associations varied by levels of glucose (187, 208, 213). Our findings for risk of 
SDPTs corroborate these observations, suggesting that prostate cancer, 
gastrointestinal and genitourinary cancers may share a common lipid metabolism 
phenotype. In the context of melanoma, few epidemiological studies have investigated 
links with lipid metabolic alterations (214). 
 
Cholesterol is necessary to build cell membrane and preclinical studies suggest that 
low levels of cholesterol cause cell cycle arrest. Furthermore, high levels of cholesterol 
induce a chronic inflammatory state, and thus potentially cell proliferation (215). 
Recent experimental data also suggest that statins, a commonly used cholesterol-
lowering drug, may impair cell proliferation and induce apoptosis (216-218).  
This excess of lipids may not only be part of the tumour phenotype of uncontrolled cell 
proliferation, but it may also be involved in the altered cell signaling activated cascades 
that are characteristic of cancer cells (219).  
 
GGT 
My results show that elevated levels of GGT measured before prostate cancer 
diagnosis are associated with higher overall SDPTs risk and more specifically with 
SDPTS of digestive organs and lung cancer. Epidemiological studies have established an 
association between GGT and several primary cancers. For instance, elevated levels of 






Several mechanisms have been suggested explaining the role of GGT in cancer cell 
proliferation and survival. Some of these processes include the recovery of essential 
aminoacids like glutamic acid and cysteine and balancing the reactive oxygen species 
ROS levels and facilitating the biosynthesis of the macromolecules and organelles 
required for assembling new cells (221). 
 
Glucose and fructosamine 
In contrast to previous findings in the AMORIS study (182), these results did not 
support a link between markers of glucose metabolism and development of SDPTs in 
men with prostate cancer. This discrepancy in findings could be due to glucose 
measurements being potentially more sensitive to the time window before 
carcinogenesis. Our previous study focused on primary tumours and hence the time 
window between glucose measurement and risk of cancer was shorter than in the 
current study (182).    
 
Summary 
Studying the common aetiology of SDPTs is broad and difficult to implement. Using 
AMORIS, and its linkages to well-documented registries, allowed me to establish a 
stable association between the biomarkers of interest and development of SDPTS – 
which informs future hypotheses for understanding the process of carcinogenesis.  
  
Unmeasured confounding can compromise the validity of observational studies. 
Usually propensity scores, regression and matching are used to reduce potential 
confounding of known variables. However, they cannot account for unknown or 
unmeasured confounders. Instrumental variables analysis is a method used for 
controlling for unmeasured confounding that requires a valid instrumental variable 
which must be independent of the unmeasured confounding; must affect the 
treatment; and can affect the outcome indirectly through its effect on the treatment. 
Genes as such can be used as instrumental variables in what is known as Mendelian 
randomization because it makes use of the random assignment of genetic variants 




current study, gene data was not available for this study and therefore adjusted Cox 
proportional hazard models were used. 
 
 
Further strengths of the present study are the large number of men with prospective 
measurements of biomarkers measured at the same clinical laboratory with a clearly 
documented methodology. Missing data, for the biomarkers studied, was limited and 
multiple imputations were used to address this. Not enough data was available to 
perform longitudinal analysis including repeated biomarker measurements, a study 
design that would benefit future studies aiming to evaluate the effect of serum 
biomarkers on development of prostate cancer and subsequent cancers. Use of 
national health registers provided complete follow-up for each person as well as 
detailed information on cancer diagnosis, time of death and emigration (223). Subjects 
included in the study were mainly healthy at baseline as these measurements were to 
a large extent part of routine health check-ups in the occupational setting. The 
selection of biomarkers followed findings in previous AMORIS studies (180-182), but 
could be widened in future studies. 
 
Prostate cancer treatment is unlikely to impact on this study as a confounder. 
Although cancer treatment potentially increases risk of SDPTs, the induction period is 
usually >5 years (224, 225). The current follow-up time was on average five years, 
suggesting that SDPTs captured were probably already being developed by the time of 
prostate cancer diagnosis.  
 
Limited data on lifestyle factors was available, however all models were adjusted for 
CCI, which indirectly accounts for effects of lifestyle (e.g., smoking-related diseases).  
However, the biomarkers themselves can also be considered a downstream of some 
lifestyle habits. Another limitation is the lack of information on drug prescriptions 
related to the biomarkers studied (e.g. anti-diabetes drugs). The Prescribed Drug 
Register only starts recording in Sweden in July 2015 (226). Adjustment for CCI can 
therefore be considered as a crude proxy for the potential use of these drugs. 




followed up by their physicians and therefore secondary tumours would have been 
detected more promptly) is not affecting this study, as we did not focus on biomarkers 
measured after prostate cancer diagnosis. Detection bias of urological cancers is 
plausible due to closer specialist follow-up, however again this does not discard a 
possible biological link. 
 
3.1.5. Conclusion 
Biomarkers of lipid metabolism as well as GGT measured before prostate cancer 
diagnosis were associated with a higher risk of developing a SDPT. In the AMORIS 
cohort, lipids and GGT (180, 181) have been previously linked with higher risk of 
prostate cancer and I can therefore suggest that SDPTs and prostate cancer could 
share common biological components, involving the metabolism or potential effect of 
lipids or GGT – a hypothesis which will require future pre-clinical as well as longitudinal 
studies to corroborate (Figure 14). 
 





4. Chapter IV: Treatment-related outcomes – results from PCBaSe 
Sweden 
 
The following three projects are all based on data from PCBaSe Sweden, so that the 
first section of this chapter describes this data resource in more detail. Next, the 
rationale, study population, research methods, and results for each specific project are 
explained.  
 
4.1. Data source: PCBaSe 
The National Prostate Cancer Register (NPCR) was formed in 1996 when several 
Swedish regional prostate cancer registers joined together. The primary aim of the 
NPCR is to provide data for quality assurance, bench marking of patient care and 
clinical research. NPCR captures >96% of all newly diagnosed, biopsy-confirmed 
prostate cancers registered in the Swedish National Cancer Register, to which 
registration is compulsory and mandated by law. Reports to the Cancer Register are 
obtained from the treating clinician and the pathology department that made 
morphological diagnosis. 
 
All new incident cases of prostate adenocarcinomas are reported to the respective 
regional register, which are also regularly linked to each Regional Cancer Register, and 
data on cases not reported to NPCR are requested from each reporting clinical unit. 
Data are validated and checked for completeness at each Regional Cancer Centre 
before being entered to the online IT platform Information Network for CAncer care 
(INCA). 
 
Prostate cancer database Sweden PCBaSe is a linkage of the records from the NPCR 
with several Swedish nationwide registers (Table 11). It was first described in 2008 and 
later on updated in 2012 and 2016 (53, 54, 227). In the following sections I only 





Table 11. PCBaSe included registers  
 
Register  Data content  
Swedish Cancer Register (1958) 
Notification of cancer diagnosis, site and date. Reporting 
mandated by law from clinician and pathology department  
Patient Register (Patient register 
regionally since 1964 and national since 
1987) 
In-patient and Out-patient Registers, with diagnostic and 
surgical codes  
Cause of Death Register (1961) 
Date and underlying and contributing causes of death coded 
according to ICD-10  
Register of the Total Population and 
Changes (1968) 
PIN for all Swedish residents, country of birth,  
Registers of Immigration and 
Emigration  
Date of immigration and emigration  
Sweden Household Census  Demographics collected 1960–90 including e.g. profession  
Longitudinal database on 
socioeconomic factors (LISA) (1990) 
Extensive set of socio-economic factors with annual update 
including data on annual income, marital status, profession and 
income  
The Prescribed Drug Register (2005) 
All non-hospital prescribed and dispensed drugs for all Swedish 
residents since July 2005  
The Multi-Generation Register (1932) 
Data on all residents born after 1932 with information on 
identity for father, mother, brothers, sisters and offspring  
National Diabetes Register  
Details on diabetes diagnosis and metabolic factors for diabetes 
in Sweden  
Hernia Register (1992) >95% of all hernia surgeries performed since 1992  
Riks-HIA/Swede Heart  
Details on cardiac diagnoses and treatment since 1995 Patients 




4.1.1. The Patient Register 
As of 1987, the National Patient Register collects information regarding in-patient care 
nationwide. Prior to this the Patient Register operated on a regional level since 1964. 
From 2001 the register also includes all specialized outpatient care. Each record 
contains medical information on surgical procedures, hospital department and 





4.1.2. The Cancer Register 
The Swedish National Cancer Register was founded in 1958. All incident cases of 
cancer in Sweden must be separately reported to the cancer register by the 
responsible clinician as well as the respective pathologist/cytologist.  
 
4.1.3. The Cause of Death Register 
The National Cause of Death Register originates since 1953. It is maintained by the 
National Board of Health and Welfare and shows underlying as well as contributory 
cause of death coded according to ICD-10 since 1997 and ICD9 before 1997. 
 
4.1.4. Population and housing census  
During the period 1960-1990 mandatory national censuses were performed in 
Sweden. This has yielded information on the individual, their household and housing, 
such as demographics, occupation, earnings, number of people per household, etc. 
Based on this information for PCBaSe, a socio-economic index can be constructed 
using five categories based on occupation: blue-collar workers, farmers, self-
employed, lower white-collar workers and higher white-collar workers.  
 
4.1.5. The Total Population Register  
The Total Population Register provides information on country of origin and 
emigration. Moreover, socio-economic characteristics in PCBaSe be defined by 
information on education level, annual family income and marital status, available 
from linkage with the Longitudinal integration database for health insurance and 
labour market studies (LISA by its Swedish acronym) The database integrates existing 
data from the labour market and educational and social sectors. 
 
4.1.6. The Prescribed Drug Register 
The Swedish Prescribed Drug Register includes all prescriptions dispensed in Swedish 
pharmacies from July 2005. Information on the prescribed item includes amount and 
dose, and age, sex and place of residence of the patient, as well as date of prescribing 




4.1.7. Comparison cohort  
The comparison cohort for these men consists of men free of prostate cancer who 
were randomly selected according to the eligibility criteria as described for each of the 
studies below. Briefly, follow-up started at time of prostate cancer diagnosis for men 
with prostate cancer (index cases) and ended at time of death, emigration or study 
closing date. For all men with prostate cancer registered between 1996 and 2009 five 
men free of prostate cancer from the same county and birth year were selected. Thus, 
for each man with prostate cancer, PCBaSe contains five matched men without 
prostate cancer. Each man with prostate cancer has a unique set of men without 
prostate cancer in the comparison cohort.  
 
4.1.8. Strengths  
NPCR captures virtually all men diagnosed with prostate cancer in Sweden since 1998. 
Including more than 110 000 cases, NPCR is the world's largest clinical database on 
prostate cancer with data available on clinical stage, specific tumour differentiation 
according to the Gleason grading and serum PSA levels in an unselected patient 
population from an entire nation.  
 
4.1.9. PCBaSe traject  
In the latest database update of PCBaSe (PCBaSeTraject), prostate cancer treatment 
trajectory is delineated by use of data on primary treatment in the NPCR, verified by 
data obtained by linkages with the Prescribed Drug Registry (i.e. use of ADT) and the 
National Patient Registry (i.e. surgical procedures and hospital admissions). In addition, 
data were collected on radiotherapy (RetroRad) from oncology information systems 
and local databases at radiotherapy departments for treatments performed before 
2008 (53). The order of treatments is the following: conservative treatment (CT) → 
radical prostatectomy → radiotherapy → anti-androgens (AA) → gonadotropin-
releasing hormone (GnRH) agonists, in which any treatment may be omitted (example 






Figure 15 Flow chart of data collection for conservative treatment in PCBaSe Traject (53, 228) 
 
 
Abbreviations: NPCR: National Prostate Cancer Register, CTWW: watchful waiting, CTAS: active surveillance, CTUNS: 






4.2. Radiotherapy and the risk of thromboembolic disease 
The findings of this section were presented as an abstract at the NCRI Conference in 
2016 (Appendix II) and published in the International Journal of Radiation Oncology, 
Biology, and Physics (Appendix III) (229). 
 
4.2.1. Rationale 
Cancer increases risk of TED as tumour cells can activate the coagulation system (230). 
Previously, it has been shown in a PCBaSe study, that men with prostate cancer are at 
higher risk of TED (231) and this risk is especially high for those who have undergone 
prostate cancer-related surgeries,  whilst receiving ADT (232).  
 
No large epidemiological study has yet investigated the association between 
radiotherapy and risk of TED. It has been suggested that veins are less susceptible to 
radiation effects, however there are several case reports of arterial thrombosis for 
patients who received radiotherapy for breast, lung or uterine cancer (233-235). There 
is also a considerable body of experimental and epidemiological evidence showing that 
radiotherapy causes damage to endothelial cells in the arteries via different 
mechanism (236). For instance, the association between radiotherapy for breast 
cancer and higher risk of myocardial infarction and coronary heart disease is well 
established (237, 238). Based on this evidence, endothelial damage to veins is possible. 
According to a systematic review TED annual incidence rates ranges from 0.75 to 2.69 
per 1000 individuals in the population, with the incidence in most of the studies 
ranging between 1.07 and 1.83. These rates increase with age and one of the main risk 
factors is cancer (239). Considering that men with localised prostate cancer have 
different treatment options (mainly AS, radical prostatectomy or RT) with curative 
intent evaluating life threatening possible treatment side effects is of high interest. 
Therefore, quantifying the risk of TED after radiotherapy is of relevance.   
 
In this study, I investigated the association between curative radiotherapy given with 
contemporary standards for prostate cancer and risk of TED in a nationwide 





4.2.2.1. Study population 
All men with prostate cancer who received curative radiotherapy for prostate cancer 
between 1996 and 2013, as registered in PCBaSe (n=9,178) (Figure 16). These men 
were matched by county of residence and birth year with an index case. For the 
current study, we selected 46,826 men free of prostate cancer. This comparison with a 
non-prostate cancer cohort has been successfully applied previously in PCBaSe when 
investigating the risk of TED, cardiovascular disease or diabetes following androgen 
deprivation therapy or surgery (54, 231, 240-242).  
 
Figure 16 Selection of study population from Prostate Cancer Database Sweden 
 
Abbreviations: EBRT: external beam radiotherapy, BT brachytherapy, PCa prostate cancer RT: radiotherapy, PCBaSe: prostate 
cancer database Sweden 
 
4.2.2.2. Exposure definition 
Radiotherapy data was obtained from the NPCR as well as from RetroRadioTherapy, a 
separate retrospective data collection at radiation units in Sweden. For this register 
data on treatment type, timing, total dose and fractionation was retrieved directly 
from the verification/oncology information systems and local databases of the 
radiotherapy departments in Sweden. Men were followed up starting on the day of RT 




men inherited a RT date according to their matched prostate cancer men. The 
Research Ethics Board at Umea University approved this study (228). 
 
The following information on potential confounders was also obtained. Based on 
information from the National Patient Register, comorbidities were measured using 
CCI, as previously described in chapter III. Information on age, serum PSA, treatment at 
time of diagnosis, tumour grade and stage, educational level, and history of TED was 
also used. Prostate cancer risk category was defined according to a modification of the 
National Comprehensive Cancer Network Guideline (243): low risk: T1–2, Gleason 
score 2–6 and PSA < 10 ng/mL; intermediate risk: T1–2, Gleason score 7 and/or PSA 
10– 20 ng/mL; high risk: T3 and/or Gleason score 8–10 and/or PSA 20–50 ng/mL; 
regionally metastatic/locally advanced: T4 and/or N1 and/or PSA 50–100 ng/mL in the 
absence of distant metastases (M0 or MX); and distant metastases: M1 and/or PSA > 
100 ng/mL. Information on surgeries was taken from the National Patient Register, and 
included transurethral resection of the prostate (TURP), open or laparoscopic radical 
prostatectomy, pelvic lymph node dissection, and orchiectomy (232). Information on 
filled prescriptions of anti-androgens and GnRH agonists was obtained from the 
National Prescribed Drug Register, in which all filled prescriptions have been registered 
since 1st of July 2005. This allowed us to create a time-updated covariate for adjuvant 
and neoadjuvant ADT. Disease progression was defined by using the following proxy 
variables as time-dependent covariates: ADT starting 9 months after RT, TURP 
indicating infravesical obstruction; palliative radiotherapy indicating a rise in serum 
PSA level or skeletal pain; and use of nephrostomy indicating overgrowth on the 
ureter. This is consistent with previously published work on the association between 
ADT and TED (241).  
 
4.2.2.3. Outcome definition 
The main outcomes were DVT (International Classification of Diseases [ICD]-10 code: 
I80-82) and PE (ICD-10: I26) as primary diagnoses in the National Inpatient Register 
and National Outpatient Register or Cause of Death Register. All three registers were 
used to avoid underestimation of severe cases of PE that may have only been captured 





4.2.2.4. Statistical analysis 
First, univariate Cox proportional hazards models were conducted to evaluate the 
association between known clinical risk factors (i.e., lymph node dissection, palliative 
radiotherapy, ADT due to disease progression, hydronephrostomy, non-prostate 
cancer related surgeries) and TED. This then confirmed the need to take these factors 
into account as time-updated covariates in our multivariate models. To further justify 
the choice for time-updated covariates related to prostate cancer only, a sensitivity 
analysis was performed in which these events were censored (e.g. androgen 
deprivation therapy for disease progression) or used delayed entry (e.g. one year 
following lymph node dissection). The results were virtually the same as for the 
adjusted models. Univariate and multivariate Cox proportional hazards models with 
age as a time-scale were then conducted to determine the hazard ratios (HR) and 95% 
confidence intervals (CI) for risk of DVT and PE by types of radiotherapy 
(brachytherapy (BT) and external beam radiotherapy (EBRT). The assumption of 
proportionality of the Cox model covariates was tested by plotting Schoenfeld 
residuals (206). The multivariate analyses were conducted stepwise, allowing the 
identification of the effect of each confounder: CCI, education, prostate cancer risk 
categories, prostate cancer-related surgeries, history of TED, disease progression 
markers, other surgeries, adjuvant and neoadjuvant ADT. Exposure to surgeries, 
neoadjuvant and adjuvant ADT and markers of disease progression were incorporated 
as time-updated covariates. Due to the rather small sample size for BT, only an 
additional stratified analysis by time since radiotherapy for EBRT: 0-6 months, 6-12 
months, 1-2 y, >2y was performed. 
 
Data management was done using SAS version 9.3 (SAS Institute, Cary, NC, USA) and 
data analysis was conducted with R version 2.13.2 (R Foundation for Statistical 
Computing, Wien, Austria). 
 
4.2.3. Results 
Between 1996 and 2013, 9,410 men received curative radiotherapy as registered in 




consisted of patients receiving either high-dose-rate BT (HDR-BT) to the prostate 
(n=2,452), combined with EBRT in the majority of the patients or low-dose-rate BT 
(LDR-BT) via implanted radioactive seeds (n=726). There were 144 TED events in the 
exposed groups (43 in the BT group and 101 in the EBRT group) and 483 in the 
comparison cohort. Baseline characteristics of the study cohort are presented in Table 
12. 
 
Univariate analyses for the association between known TED risk factors and PE and 
DVT are presented in Table 13, confirming the need for time-updated covariates in the 
multivariate analyses. 
 
There was a positive association between EBRT and BT and the risk of PE, although 
after adjusting for CCI, prostate cancer risk category, prostate cancer-related surgeries, 
previous TED, disease progression markers, other surgeries, education, adjuvant ADT 
and neoadjuvant ADT it was no longer statistically significant (HR: 1.05, 95% C.I.: 0.61-
1.79 and HR: 0.97, 95%C.I.: 0.29-1.44 respectively) (Table 14). In the stratified analysis, 
the highest HR was observed for the first period (0 to 6 months), however after 
adjustment for the named covariates it remained not statistically significant. No 
associations between EBRT or BT and the risk of DVT were found. Residual plots for all 
covariates versus time at risk showed the residuals centred around zero, indicating no 





Table 12. Radiotherapy and TED study participant’s baseline characteristics 
 
 
BT EBRT PCa free men 
 
# % # % # % 
Total number of men 3178 100 6232 100 46826 100 
Age  
      
<60 490 15.4 566 9.1 5299 11.3 
60-64 772 24.3 1179 18.9 9678 20.7 
65-74 1747 55.0 3827 61.4 27706 59.2 
75+ 169 5.3 660 10.6 4143 8.8 
CCI 
      
0 2574 81.0 4632 74.3 35975 76.8 
1 382 12.0 935 15.0 5751 12.3 
2 158 5.0 436 7.0 2944 6.3 
3+ 64 2.0 229 3.7 2156 4.6 
Stage Group 
      
No PCa 0 0.0 0 0.0 46826 100.0 
1. Low risk 864 27.2 900 14.4 0 
 
2. Intermediate risk 1059 33.3 2387 38.3 0 
 
3. High risk 1106 34.8 2503 40.2 0 
 
4. Regionally metastatic 126 4.0 391 6.3 0 
 
6. Missing data 23 0.7 51 0.8 0 
 
Prior DVT 
      
0 3171 99.8 6190 99.3 46529 99.4 
1 7 0.2 38 0.6 140 0.3 
2+ 0 0.0 4 0.1 157 0.3 
Prior PE 
      
0 3151 99.2 6157 98.8 46497 99.3 
1 26 0.8 65 1.0 146 0.3 
2+ 1 0.0 10 0.2 183 0.4 
Neo adjuvant ADT 
      
No ADT 1029 32.4 2463 39.5 46826 100.0 
 Anti androgens 200 6.3 309 5.0 0 
 
 GnRH 1949 61.3 3460 55.5 0 
 
Educational level 
      
Low 869 27.3 2279 36.6 16861 36.0 
Middle 1333 41.9 2525 40.5 18684 39.9 
High 959 30.2 1388 22.3 10652 22.7 
Missing 17 0.5 40 0.6 629 1.3 
Follow-up time (SD) 








Adjuvant ADT: BR group (AA=222 GnRH=134) EBRT group (AA=484, GnRH=678)  
Abbreviations: CCI: Charlson Comorbidity Index, ADT: Androgen Deprivation therapy; DVT: Deep Venous Thrombosis, PE; Pulmonary Embolism, GnRH: Gonadotropin releasing 







Table 13. Univariate hazard ratios (HR) and 95% confidence intervals (CI) for risk of DVT and PE based on known 
clinical risk factors for TED. 
 
    Univariate 
TED known risk factors Number of events PE DVT 







Lymph node dissection  
(LND within last 12 months 
versus no LND within last 12 
months) 
759 1166 2.03 0.82-4.99 3.44 0.80-14.76 
Palliative RT 25 90 1.68 0.23-12.06 17.72 4.16-75.47 
AA due to disease 
progression vs. no AA 
181 665 1.09 0.50-2.58 2.64 0.92-7.56 
GnRH due to disease 
progression 
183 537 2.46 1.30-4.65 9.41 3.83-23.06 
Hydronephrostomy 4 24 7.56 1.03-55.44 NA* NA 
 














      
*No events 
**PCa-free men included for this variable (Nr of events=5106) 
TED: Thromboembolic diseases, BT: Brachytherapy, EBRT: External beam radiotherapy, PE: Pulmonary embolism, DVT; Deep 
venous thrombosis, HR: Hazard ratio, CI: confidence intervals, NA: non applicable, AA: Anti-androgens, GnRH: Gonadotropin 






Table 14. Multivariate analysis hazard ratios (HR) and 95% confidence intervals (CI) for risk of DVT and PE. 
 
  DVT PE 
  HR 95%CI HR 95%CI 
Ref No RT 1.00 Ref. 1.00 Ref. 
Unadjusted 
BT 0.60 0.26-1.36 1.47 1.05-2.07 
EBRT 1.09 0.68-1.74 1.73 1.35-2.2 
Adjusted* 
BT 0.34 0.08-1.11 0.97 0.29-1.44 
EBRT 0.44 0.14-1.4 1.05 0.61-1.79 
*Charlson comorbidity index ,PCa risk category,  PCa-related surgeries, previous thromboembolic events, TED known risk factors 







The current study shows that in a cohort of Swedish men with prostate cancer, 
curative radiotherapy for prostate cancer was not associated with an increased risk of 
TED.  This study’s analyses compare men with prostate cancer receiving RT with 
matched men from the general population, so that these results cannot disentangle 
the effects of RT and the tumour itself on development of TED. The observed lack of an 
association between RT and TED when comparing with the general population can be 
explained by one of the following reasons: (1) RT is truly not associated with risk of 
TED;(2) Men on RT are heavily selected based on their TED risk factors so that a 
potential increased risk of TED from RT is at most as big as the risk reduction due to 
the selection. However, as cancer itself is a risk factor for TED, this indicates that the 
second explanation is unlikely. 
 
To the best of my knowledge, no large study to date has investigated the association 
between RT for prostate cancer and TED. Experimental data shows that radiotherapy 
can induce changes in artery walls, sinusoids and capillaries (236). The different layers 
of the wall vessels can suffer several alterations after radiation exposure such as 
endothelial cell damage, neointima lipid deposit, necrosis, fibrosis rupture and 
thrombosis (236, 244). Moreover, EBRT to the pelvis has been found to increase the 
risk of bleeding in men who were on an anticoagulant scheme before receiving RT 
(245). Less evidence has been found for large veins (246), except for hepatic and large 
intestine veins, which radiotherapy frequently affects. Little is known regarding the 
biological mechanisms for this lesser impact of RT in large veins, although it has been 
suggested that large veins that do get affected by RT were probably invaded by the 
neoplasm prior to RT (246). Our results suggest that large veins from the pelvic area of 
patients who received RT for prostate cancer do not seem to suffer enough alterations 
that can lead to a short-term thromboembolic event. However most of the reported 
RT changes in the arteries and heart seem to happen several years after receiving RT, 
and our mean follow up time was 5 years, so that the present study may not be 





Men who undergo radical prostatectomy are at a slightly increased risk of TEDs (231). 
Moreover, results from a recent observational showed that ADT also increases the risk 
of TED (241). In my analysis, I included adjuvant and neoadjuvant ADT as potential 
confounders, however this adjustment did not alter the final point estimates for the 
association.  
 
A major strength of this study is the use of comprehensive data in PCBaSe Sweden, a 
large nationwide population-based register from which information on complete 
follow-up, prostate cancer treatment, prostate cancer stage, surgeries, disease 
progression, ADT, comorbidities and socio-economic status can be retrieved, which 
allowed me to adjust for known TED risk factors. Additionally, the use of a prostate 
cancer-free, age and residence matched comparison cohort allowed for accurate risk 
estimation. The availability of data regarding delivered radiotherapy doses for this 
large cohort is another strength of this study. It allowed us to confirm that the selected 
patients had received radiation doses with curative potential to the prostate.   
 
Detailed information on irradiated volumes was lacking which excluded the possibility 
to examine dose-volume effects on TED. Even though we had data on type and dosage 
of EBRT, it was not possible to divide this further into subtypes due to the low number 
of TED events. However, it is unlikely that we have missed strong associations as none 
of our findings suggested any indication of a positive trend. Additional limitations 
include lack of information on lifestyle factors and residual confounding, which could 
not be accounted for (247, 248). However, adjustment for CCI and history of TED 
served as proxies for lifestyle and health status at initiation of RT. Furthermore, as it 
can be observed baseline characteristics amongst EBRT, BT and the comparison cohort 
are very similar, reducing the amount of residual confounding. 
 
4.2.5. Conclusion 
These results indicate that curative radiotherapy for prostate cancer is not associated 





4.3. Drugs for metabolic conditions and prostate cancer death in men on GnRH 
agonists 
The findings of this section were published in the BJU International (Appendix IV) (249). 
 
4.3.1. Rationale 
A recent meta-analysis estimated that the risk of prostate cancer is 1.54 times (95%CI: 
1.23-1.94) higher for those with MetS, as compared to those without MetS (250). 
Recent studies also suggest that the presence of MetS or some of its features is 
associated with higher grade disease in men with prostate cancer and can lead to 
more rapid progression (163, 251).  Moreover, in a review on the urological aspects of 
MetS authors found evidence linking the following conditions to prostate cancer: 
Increased fasting plasma insulin level, higher BMI, increased body weight, increased 
waist measurement, increased hip measurement, increased waist: hip ratio, type 2 
diabetes, faster growing BPH, treated hypertension, higher systolic blood pressure, 
higher diastolic blood pressure, lower serum HDL-cholesterol level, increased serum 
triglycerides levels (252). 
 
In contrast, some drugs used to treat conditions that are part of the MetS definition 
(e.g. metformin for diabetes or statins for dyslipidemia) have also been associated with 
a reduced risk and progression of prostate cancer (253-256) although results are not 
conclusive. For instance, in a study looking at metformin vs. sulfonylureas and their 
association with cancer incidence no differences were found(257). Nonetheless, the 
underlying biological mechanisms for these observations have not been fully 
elucidated (258).  
 
GnRH agonists are associated with an increased risk of type 2 diabetes as well as other 
components of the MetS in men with prostate cancer who are treated with ADT (161).  
Moreover, one recent study found that that having MetS may shorten time to castrate 
resistant prostate cancer and overall survival (163), whereas another study did not find 
any statistically significant associations between baseline MetS and prostate cancer 





Given this complex interaction between MetS, its related drugs, and prostate cancer 
progression, the current study aimed to evaluate how use of drugs for metabolic 
conditions (below referred to as “metabolic drugs”) at time of GnRH agonist initiation 
may affect response to treatment by studying time to prostate cancer death. 
 
4.3.2. Methods 
4.3.2.1. Study population 
All men with prostate cancer who received primary GnRH agonists between 2007 and 
2013 (n=9,267), as registered in PCBaSe Traject (228) were selected. 
 
4.3.2.2. Exposure definition 
The main exposure variables for this study were newly filled prescriptions, prescribed 
before GnRH agonist initiation, for treatment of diabetes (metformin, sulphonylurea, 
insulin), dyslipidaemia (statins), hypertension (angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, or 
thiazide and thiazide-like diuretics), or anti-obesity agents in the Prescribed Drug 
Register. As only 20 men received anti-obesity agents, exposure to these drugs was not 
considered as part of the analysis a priori. As many men often take drugs for more 
than one of the metabolic conditions listed above, we looked at each metabolic drug 
group individually as well as the most common combinations: dyslipidaemia only 
(n=241), hyperglycaemia only (n=67 ;38 on insulin and 29 on metformin or 
sulphonylurea), hypertension only (n=2,933), dyslipidaemia and hyperglycaemia 
(n=41), dyslipidaemia and hypertension (n=1,996), hyperglycaemia and hypertension 
(n=333), and treated for more than two metabolic conditions (n=651). The analyses 
focused on the four most common groups of drugs: hypertension only, hypertension 






Figure 17 Combinations of metabolic drugs studied 
 
 
The following information on potential covariates was also obtained: age, tumour 
grade and stage and educational level. Prostate cancer risk category was defined 
according to a modification of the National Comprehensive Cancer Network Guideline 
(243): low risk: T1–2, Gleason score 2–6 and PSA < 10 ng/mL; intermediate risk: T1–2, 
Gleason score 7 and/or PSA 10– 20 ng/mL; high risk: T3 and/or Gleason score 8–10 
and/or PSA 20–50 ng/mL; regionally metastatic/locally advanced: T4 and/or N1 and/or 
PSA 50–100 ng/mL in the absence of distant metastases (M0 or MX); and distant 
metastases: M1 and/or PSA > 100 ng/mL.  In addition, we collected information on 
history of CVD, defined by any CVD hospital admission (ICD-10 codes: I20-I25, I50, I60-
I69, I70-I79) as primary diagnoses in the National Patient Register. Comorbidities were 
also measured using CCI. Individuals were grouped into CCI categories for final scores 
of 0, 1, 2 or 3+. History of CVD and CCI were included for descriptive purposes, as 
careful assessment of the causal pathway did not indicate that these covariates need 
to be included in multivariate models (Figure 18) (259).   
 
4.3.2.3. Outcome definition 
Based on the underlying causes of death registered in the Cause of Death Register, the 
following main outcomes were defined for this study: death from prostate cancer (ICD-
10:C61), death from cardiovascular disease (CVD) (ICD-10: I10 to I99), as well as other 













4.3.2.4. Statistical analysis 
Univariate and multivariate Cox proportional hazard regression models were 
conducted to assess the association between individual metabolic drugs as well as 
common combinations (Figure 18) and death from prostate cancer, CVD and overall 
mortality. Multivariate models were adjusted for age, education level, disease stage 
and civil status. Adjustment for age was done using natural cubic splines with four 
degrees of freedom. To consider competing risks, we repeated the analyses using Fine 
and Grays competing risk regression (260).  
 
To further illustrate the associations between metabolic drugs and causes of death, 
stacked cumulative incidence proportion functions for all-cause, CVD, and prostate 
cancer -specific death were displayed by categories of metabolic drug use. 
 
Figure 18 Directed acyclic graph for the association between metabolic drugs and prostate cancer death in men who 
start on GnRH agonists. 
 
 
Data management was performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) 
and data analysis was conducted with R version 2.13.2 (R Foundation for Statistical 





A total of 6,322 (68%) men used at least one drug for a metabolic condition at the time 
they started GnRH agonists. The majority of these men were on antihypertensive drugs 
only (46%), followed by men on drugs for dyslipidemia and hypertension (32%). About 
10% of men were on drugs for more than two metabolic conditions. Table 15 shows 
the baseline characteristics of all men included in the study based on the type of 
metabolic drugs they were taking at time of GnRH agonist initiation.  
 
Multivariate Cox proportional hazards regression adjusted for age, education, and 
prostate cancer risk category showed that use of most metabolic drugs were 
associated with an increased risk of CVD death and hence also overall death (Table 16). 
For instance, those men on anti-hypertensive drugs only were 1.87 times more likely 
to die of CVD than men not taking any metabolic drugs (95%CI: 1.56-2.24) and this 
increased to 2.46 times if these men were also taking drugs for dyslipidaemia (95%CI: 
2.03-2.98). With respect to prostate cancer death, a small increased risk was observed 
for those on drugs for hypertension only or any hyperglycaemia (HR: 1.12 (95%CI: 
1.03-1.23) and 1.19 (95%CI: 1.06-1.35), respectively). 
 
Given the strong association with death from CVD, competing risk regression showed 
little impact on the association between metabolic drugs and death from CVD (Table 
17). However, the associations observed for prostate cancer death disappeared for 
those on drugs for hypertension and dyslipidaemia, (HR: 0.92 (95%CI: 0.83-1.02)).  
 
Figure 19 illustrates these findings using stacked cumulative incidence proportions. 
The largest proportion of CVD-deaths (red) can be observed amongst those on 
metabolic drugs, with the biggest proportion for those who are on drugs for both 
hypertension and statins. The proportion of prostate cancer -deaths (blue) was fairly 









































 N % N % N % N % N % N % N % N % N % N % 
Age                      
<65 896 (9.7) 15 (6.2) 7 (10.4) 2 (5.3) 5 (17.2) 17
5 
(6.0) 5 (12.2) 112 (5.6) 19 (5.7) 40 (6.1) 
65-74 259
9 
(28.0) 76 (31.5) 28 (41.8) 18 (47.4) 10 (34.5) 65
1 
(22.2) 12 (29.3) 548 (27.5) 76 (22.8) 217 (33.3) 
75-84 420
9 
(45.4) 133 (55.2) 29 (43.3) 17 (44.7) 12 (41.4) 13
68 
(46.6) 21 (51.2) 1068 (53.5) 173 (52.0) 319 (49.0) 
85+ 156
3 
(16.9) 17 (7.1) 3 (4.5) 1 (2.6) 2 (6.9) 73
9 
(25.2) 3 (7.3) 268 (13.4) 65 (19.5) 75 (11.5) 
CCI                                         
0 575
5 
(62.1) 150 (62.2) 33 (49.3) 24 (63.2) 9 (31.0) 18
57 
(63.3) 17 (41.5) 827 (41.4) 124 (37.2) 179 (27.5) 
1 168
3 
(18.2) 55 (22.8) 18 (26.9) 8 (21.1) 10 (34.5) 4
5 
(18.6) 12 (29.3) 607 (30.4) 77 (23.1) 151 (23.2) 
2 983 (10.6) 25 (10.4) 10 (14.9) 5 (13.2) 5 (17.2) 31
3 
(10.7) 6 (14.6) 278 (13.9) 57 (17.1) 133 (20.4) 
3+ 846 (9.1) 11 (4.6) 6 (9.0) 1 (2.6) 5 (17.2) 21
8 




     
        




(15.2) 52 (21.6) 9 (13.4) 4 (10.5) 5 (17.2) 42
5 
(14.5) 9 (22.0) 283 (14.2) 30 (9.0) 78 (12.0) 
Low 455
1 
(49.1) 104 (43.2) 34 (50.7) 22 (57.9) 12 (41.4) 15
07 
(51.4) 21 (51.2) 999 (50.1) 194 (58.3) 333 (51.2) 
Middle 3 7
2 
(34.2) 81 (33.6) 24 (35.8) 12 (31.6) 12 (41.4) 96
0 
(32.7) 9 (22.0) 699 (35.0) 104 (31.2) 229 (35.2) 
Missing 133 (1.4) 4 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 41 (1.4) 2 (4.9) 15 (0.8) 5 (1.5) 11 (1.7) 
Civil status,                                         
Married 566
4 
(61.1) 157 (65.1) 33 (49.3) 17 (44.7) 16 (55.2) 17
76 
(60.6) 28 (68.3) 1284 (64.3) 183 (55.0) 411 (63.1) 
Not married 360
3 
(38.9) 84 (34.9) 34 (50.7) 21 (55.3) 13 (44.8) 11
57 
(39.4) 13 (31.7) 712 (35.7) 150 (45.0) 240 (36.9) 
Risk category   
     
        
         
  
Low risk 98 (1.1) 6 (2.5) 1 (1.5) 1 (2.6) 0 (0.0) 33 (1.1) 2 (4.9) 26 (1.3) 2 (0.6) 9 (1.4) 
Intermediate 
risk 
778 (8.4) 33 (13.7) 5 (7.5) 4 (10.5) 1 (3.4) 26
3 
(9.0) 1 (2.4) 200 (10.0) 29 (8.7) 68 (10.4) 
High risk 297
6 
(32.1) 80 (33.2) 22 (32.8) 14 (36.8) 8 (27.6) 10
18 





(15.5) 32 (13.3) 14 (20.9) 6 (15.8) 8 (27.6) 44
2 
(15.1) 4 (9.8) 309 (15.5) 63 (18.9) 91 (14.0) 




(42.9) 90 (37.3) 25 (37.3) 13 (34.2) 12 (41.4) 11
77 
(40.1) 17 (41.5) 753 (37.7) 117 (35.1) 260 (39.9) 





Table 16. Cox proportional Hazard Ratios and Competing risks regression Ratios with 95% confidence intervals (CI) 
for the associations between drugs for metabolic conditions and prostate cancer death, other deaths, CVD deaths 
and overall death. 







No of events HR  95% CI HR  95% CI HR  95% CI 
Prostate cancer death        
No metabolic drugs 1117 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 986 0.97 0.89 - 1.06 1.12 1.03-1.23 1.03 0.94-1.13 
Hypertension+ Dyslipidaemia 578 0.81 0.74 - 0.90 1.02 0.93-1.14 0.92 0.83-1.02 
Hyperglycaemia 336 0.93 0.82 - 1.05 1.19 1.06-1.35 1.00 0.89-1.14 
Only Statins 73 0.78 0.62 - 0.99 1.06 0.83-1.34 1.01 0.80-1.29 
Other death        
No metabolic drugs 294                      1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 394            1.48 1.27 - 1.72 1.23 1.05 - 1.43 1.12 0.96 - 1.31 
Hypertension+ Dyslipidaemia 238               1.29 1.09 - 1.53 1.20 1.01 - 1.43 1.07 0.90 - 1.27 
Hyperglycaemia 185                     1.97 1.64 - 2.37 1.85 1.53 - 2.22 1.59 1.32 - 1.91 
Only Statins 31 1.26 0.87 - 1.82 1.23 0.85 - 1.79 1.19 0.83 - 1.72 
CVD Death        
No metabolic drugs 174                1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 385                 2.45 2.05 - 2.93 1.87 1.56 - 2.24 1.71 1.43 - 2.05 
Hypertension+ Dyslipidaemia 283   2.59 2.14 - 3.13 2.46 2.03 - 2.98 2.26 1.87 - 2.74 
Hyperglycaemia 149            2.69 2.16 - 3.35 2.53 2.03 - 3.16 2.15 1.72 - 2.69 
Only Statins 15 1.03 0.61 - 1.74 1.06 0.63 - 1.80 1.01 0.59 - 1.71 
Overall Death        
No metabolic drugs 1585               1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 1765                  1.23 1.15 - 1.31 1.22 1.14-1.31 N/A N/A 
Hypertension+ Dyslipidaemia 1099   1.10 1.02 - 1.18 1.23 1.14-1.33 N/A N/A 
Hyperglycaemia 670           1.32 1.20 - 1.44 1.49 1.36-1.63 N/A N/A 
Only Statins 119 0.90 0.74 - 1.08 1.08 0.89-1.30 N/A N/A 





Table 17. Cox proportional Hazard Ratios and Competing risks regression Ratios with 95% confidence intervals (CI) 
for the associations between drugs for metabolic conditions and prostate cancer death, other deaths, CVD deaths 
and overall death – stratified by M1. 
 






METASTATIC DISEASE ONLY   
 
 No of events HR 95% CI HR 95% CI HR 95% CI 
Prostate cancer death        
No metabolic drugs 820 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 614 1.12 1.01 - 1.24 1.07 0.96 - 1.2 0.99 0.88 - 1.1 
Hypertension+ Dyslipidaemia 361 0.98 0.87 - 1.11 1.01 0.89 - 1.14 0.91 0.81 - 1.04 
Hyperglycaemia 204 1.13 0.97 - 1.32 1.16 0.99 - 1.36 0.97 0.83 - 1.14 
Only Statins 48 1.07 0.8 - 1.43 1.11 0.83 - 1.49 1.05 0.78 - 1.42 
Other death        
No metabolic drugs 105 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 124 1.78 1.37 - 2.30 1.41 1.08 - 1.84 1.30 0.99 - 1.70 
Hypertension+ Dyslipidaemia 69 1.48 1.09 – 2.00 1.34 0.98 - 1.82 1.22 0.90 - 1.67 
Hyperglycaemia 50 2.20 1.57 - 3.09 1.95 1.39 - 2.75 1.63 1.16 - 2.30 
Only Statins 0 1.40 0.68 - 2.86 1.28 0.62 - 2.63 1.18 0.58 - 2.43 
CVD Death        
No metabolic drugs 59 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 118 2.99 2.19 - 4.09 2.06 1.50 - 2.83 1.90 1.38 - 2.61 
Hypertension+ Dyslipidaemia 78 2.97 2.12 - 4.16 2.58 1.83 - 3.64 2.38 1.69 - 3.35 
Hyperglycaemia 50 3.90 2.67 - 5.68 3.31 2.26 - 4.85 2.77 1.90 - 4.06 
Only Statins 6 1.86 0.80 - 4.32 1.64 0.71 - 3.81 1.57 0.69 - 3.54 
Overall Death        
No metabolic drugs 984 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 856 1.30 1.19 - 1.43 1.18 1.07 - 1.29 N/A N/A 
Hypertension+ Dyslipidaemia 508 1.15 1.04 - 1.28 1.14 1.03 - 1.28 N/A N/A 
Hyperglycaemia 304 1.41 1.24 - 1.61 1.40 1.23 - 1.59 N/A N/A 
Only Statins 62 1.15 0.89 - 1.49 1.16 0.90 - 1.50 N/A N/A 
NON-METASTATIC DISEASE ONLY  
Prostate cancer death        
No metabolic drugs 297 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 372 1.16 1.00 - 1.36 1.22 1.05 - 1.43 1.14 0.97 - 1.32 
Hypertension+ Dyslipidaemia 217 0.96 0.81 - 1.15 1.08 0.9 - 1.29 0.96 0.81 - 1.14 
Hyperglycaemia 132 1.14 0.93 - 1.40 1.26 1.03 - 1.55 1.09 0.89 - 1.34 
Only Statins 25 0.79 0.53 - 1.20 0.96 0.64 - 1.44 0.95 0.64 - 1.42 
Other death        




Only Hypertension 270 1.32 1.10 - 1.59 1.15 0.95 - 1.38 1.04 0.86 - 1.26 
Hypertension+ Dyslipidaemia 169 1.17 0.95 - 1.44 1.14 0.92 - 1.40 1.00 0.81 - 1.23 
Hyperglycaemia 135 1.81 1.45 - 2.26 1.78 1.43 - 2.22 1.55 1.25 - 1.94 
Only Statins 23 1.15 0.74 - 1.77 1.20 0.77 - 1.85 1.17 0.76 - 1.79 
CVD Death        
No metabolic drugs 115 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 267 2.15 1.73 - 2.68 1.77 1.42 - 2.21 1.63 1.30 - 2.03 
Hypertension+ Dyslipidaemia 205 2.33 1.86 - 2.93 2.37 1.88 - 2.98 2.19 1.73 - 2.76 
Hyperglycaemia 99 2.19 1.67 - 2.86 2.22 1.69 - 2.91 1.90 1.45 - 2.50 
Only Statins 9 0.74 0.38 - 1.46 0.84 0.43 - 1.67 0.79 0.40 - 1.57 
Overall death        
No metabolic drugs 601 1.00 Ref 1.00 Ref 1.00 Ref 
Only Hypertension 909 1.40 1.26 - 1.55 1.30 1.17 - 1.44 N/A N/A 
Hypertension+ Dyslipidaemia 591 1.29 1.15 - 1.45 1.35 1.20 - 1.51 N/A N/A 
Hyperglycaemia 366 1.55 1.36 - 1.77 1.62 1.42 - 1.84 N/A N/A 
Only Statins 57 0.90 0.68 - 1.18 1.02 0.78 - 1.34 N/A N/A 












Traditional Cox proportional hazards model indicated a weak increased risk of prostate 
cancer death in men who are on drugs for hypertension or hyperglycaemia at the time 
they start GnRH agonists. However, upon taking into account competing risk from CVD 
death none of the drugs for metabolic conditions were associated with an increased 
risk of prostate cancer death – and a trend towards an inverse association was 
observed for those who were on drugs for both hypertension and dyslipidaemia.  
 
To my knowledge, few studies have investigated the effect of drugs for metabolic 
conditions in relation to response to treatment for men on GnRH agonists (261). Most 
studies to date have explored the effect of single drugs, predominantly metformin, 
statins, or beta-blockers, in relation to prostate cancer death (218, 254, 262-268). 
Moreover, these existing observational studies have found contradicting results – and 
they did not specifically study those men on GnRH agonists, a drug that in itself is also 
associated with an increased risk of metabolic conditions (161). Some reasons for 
these contrasting findings have been summarised previously (256), but by investigating 
several drugs for metabolic conditions in a specifically defined group of men with 
prostate cancer, the current study aims to improve our understanding of possible 
associations to metabolic drugs in the context of prostate cancer progression. 
 
These results are in line with a small study (n=273) investigating the effect of metabolic 
syndrome (without looking at the related drugs) on prostate cancer death in men on 
ADT using data from the Health Professionals Follow-up Study and the Veteran’s 
Administration (164). The authors concluded that there was no association of prostate 
cancer-specific death and metabolic syndrome, but the latter was associated with an 
increased risk of death from all causes. However, there was a weak positive association 
between hypertension only and prostate cancer-specific death (HR: 1.59 (95%CI: 0.89-
2.84)). Even though the exposure assessment in this study is different from what I have 
done here, none of the studies support a strong association between metabolic 
aberrations and prostate cancer -specific death in men on GnRH agonists. The latter is 
relevant from a clinical point of view and could inform future studies looking into how 




agonists (as an adverse event) may affect response to hormonal treatment or prostate 
cancer progression.  
 
Some of the medications used in this study as proxies for metabolic syndrome 
components have been associated with reduced overall and CVD mortality when 
compared to no treatment or placebo. Therefore, the drugs could potentially impact 
on mortality differently than the syndrome itself. In my study, no beneficial effect was 
observed for any of the metabolic scores. Although it is difficult to distinguish whether 
these findings are the result of the drugs or the diseases on the outcomes, the lack of 
inverse associations may reflect that our observations are indeed the effect of the 
diseases rather than the drugs.  Another point to consider is the short follow-up time, 
which could also be preventing us from seeing the effects of the medications on 
overall/CVD mortality. 
 
A major strength of our study is the use of comprehensive data in PCBaSe Sweden. As 
with other currently published studies, our follow-up was rather short and a follow-up 
study might provide more power to investigate risk of prostate cancer death in a 
competing risk setting. Another limitation of the current study is the lack of direct 
measures of metabolic syndrome (e.g. serum glucose and cholesterol levels (256)) and 
information on lifestyle factors  
 
4.3.5. Conclusion 
Despite the suggested complex interaction between metabolic syndrome, metabolic 
drugs, and prostate cancer progression, the current study did not find any evidence for 
a better or worse response to GnRH agonists in men who were also on drugs for 
hypertension, dyslipidaemia, or hyperglycaemia. These findings suggest that treatment 
of metabolic syndrome is important in men on GnRH agonists, but not a 




4.4. Anti-androgens versus GnRH agonists in relation to prostate cancer death  
The findings of this section were submitted as an abstract for the European Urology 




Currently, the recommended treatment for men with advanced, non-metastatic 
prostate cancer is radiotherapy with adjuvant hormonal therapy (17). However, a 
substantial number of men with non-metastatic prostate cancer start primary 
hormonal therapy without radiotherapy, especially men with PSA levels above 50 
ng/mL and/or locally advanced prostate cancer (clinical local stage T3-4) (269). 
Moreover, around 20% of men diagnosed with localised prostate cancer who received 
primary curative treatment will require hormonal therapy within 10 years (270). 
 
The two main types of ADT for advanced, non-metastatic prostate cancer are medical 
castration by use of GnRH agonists and non-steroidal anti-androgen monotherapy 
(AA)(17). Presently, both types of medications are approved as monotherapies in 
Europe. Nonetheless, the European Urology Association, does not recommend AA in 
their prostate cancer guidelines based on a Cochrane systematic review results (168). 
However, the subgroup analysis of the Cochrane results showed no statistical 
differences in overall survival between bicalutamide and medical castration for non-
metastatic disease and for bicalutamide 150mg/daily. No analysis was performed for 
disease stage or dose for cancer specific survival due to lack of data. 
Therefore, large-scale evidence comparing AA vs GnRH for men with locally advanced 
non-metastatic disease in terms of overall survival and cancer specific survival is 
lacking.  
 
Previously, two RCTs have compared the efficacy as well as the adverse events profile 
between AA monotherapy and GnRH agonists. Briefly, these RCTs compared AA in the 
form of bicalutamide 150 mg/daily and GnRH agonists or maximal androgen blockade 




requirement for non-inferiority was not met, survival was similar between AA and 
GnRH agonists, and AA with bicalutamide 150 mg/daily, which is in line with the 
Cochrane review subgroup analysis, and was subsequently approved for use in men 
with advanced, non-metastatic prostate cancer by the European Medicines Agency 
(167).  
 
In addition to RCTs, it has now been widely accepted that observational data, i.e. real 
world data, are important in clinical decision making (271). It has been shown 
repeatedly that patients in RCTs are highly selected and have a lower risk profile than 
real-world populations, with the frequent exclusion of elderly patients and patients 
with co-morbidities (272-275). Supplementing RCT evidence with data generated from 
observational settings (e.g. registry data) can also improve the external validity of 
oncology drug trials, such that physicians treating patients in real-world settings have 
the appropriate evidence on which to base their clinical decisions (272, 274, 275).  
 
As AAs present with less severe adverse effects than GnRH agonists, comparing their 
results in terms of prostate cancer specific survival and overall survival is important. 
Thus, in order to assess the external validity of these early RCTs on AA monotherapy 




4.4.2.1. Study population 
Men diagnosed with high-risk or regionally metastatic prostate cancer in 2006-2012, 
i.e. clinical local stage T3 or higher and/or prostate specific-antigen (PSA) 20 ng/mL or 
higher and/or Gleason Grade Group 4-5 and/or N1 and M0/X, who received AA or 
GnRH agonists as primary hormonal therapy were included in the study. 
 
4.4.2.2. Exposure definition 
The main exposure, i.e. type of hormonal therapy, as well as conversion from AA to 




Drug Registry. To mimic the RCT setting, men older than 90 years and men with a 
history of a previous cancer diagnosis were excluded.  
 
4.4.2.3. Outcome definition 
Follow-up was calculated from date of prostate cancer diagnosis until death, 
emigration, or date of censoring, whichever event came first. Date of censoring was 31 
December 2013 for analysis of prostate cancer mortality and 31 December 2014 for 
all-cause mortality.  
 
4.4.2.4. Statistical methods 
Given that the study population of interest was men with M0 prostate cancer, it was 
important to evaluate those with missing data for M stage. Several other covariates 
had limited missing data, so therefore we first performed multiple imputation using 
the MICE package (200) based on data from men with intermediate-risk, high-risk, 
regionally metastatic and metastatic prostate cancer (i.e. four distinct risk categories) 
treated with primary hormonal therapy (Table 17). A series of univariate marginal 
models were specified to impute each of the variables with missing data: education 
(1.0-1.8%; range of messiness over the four risk categories), mode of detection (2.7-
3.4% missing), PSA (0. -1.9% missing), Gleason Grade Groups (5.3-9.0% missing), 
percentage of positive biopsies (19.5-28.9% missing), T stage (0.8-1.2% missing), N 
stage (0.2-0.4% missing) and M stage (30.8-60.1% missing as diagnostic imaging was 
not performed). The model also included all the complete variables: age at diagnosis, 
year of diagnosis, civil status, cause of death, censoring and time-to-event i.e. death. 
The number of multiple imputations was set to five with 50 iterations, and 
convergence was diagnosed (data not shown). All subsequent analyses were 
conducted on the imputed data sets including men originally categorized with high-risk 
or regionally metastatic prostate cancer, but excluding men with imputed M1 disease 
(as per inclusion criteria described above).  





As there is a potential to convert to GnRH agonists after primary AA, we first used the 
cumulative incidence proportions to quantify conversion to GnRH agonists, considering 
death from prostate cancer and other causes and conversion to GnRH as competing 
events. Cumulative incidence proportions of death from prostate cancer and death 
from other causes for men on both treatments was calculated considering these as 
competing events.  
 
Next, uni- and multivariable Cox proportional hazards regression analyses were 
conducted for death of prostate cancer and death from all causes. Age was used as 
timescale, whilst adjusting for year of diagnosis (continuous), mode of detection 
(categorical), T stage (categorical), Gleason Grade Groups (categorical), proportion 
positive biopsy cores (modelled as an interaction with T stage in men not diagnosed 
following TUR-P with two spine knots), PSA at diagnosis (categorical), bone imaging 
performed (dichotomized), CCI (categorical), marital status (categorical) and education 
level (categorical). Results are presented as Hazard ratios (HR) with 95% CIs.  
 
Then, in order to mimic a potential target trial by conducting additional Cox model 
analysis based on propensity score matching for type of hormonal therapy. Propensity 
score matching was done with the MatchIt package for R using a caliper of 0.1 and 
included the covariates enumerated above. Subsequent multivariate Cox proportional 
hazards regression analyses were performed adjusting for the covariates used to 
perform the propensity score matching. 
 
Finally, Kaplan-Meier estimates of prostate cancer-specific and overall survival were 
calculated for the propensity score matched groups and used to assess the cumulative 
deaths from prostate cancer and all causes. 
 
The Research Ethics Board at Umeå University Hospital approved the study. 
 
 Statistical analysis was performed with R version 3.1.2 (R Foundation for Statistical 





4.4.3. Results  
The study population consisted of 2,078 men on AA and 4,878 men on GnRH agonists 
as primary hormonal therapy. The median follow-up was 4.7 years, representing a 
total of 28,315 person-years. Men treated with AA were younger, diagnosed in more 
recent calendar years, had less adverse cancer characteristics and had higher 
education level, compared to men treated with GnRH agonists (Table 19).  
Virtually all men (99%) managed with AA received bicalutamide 150 mg/daily. In total, 
765 men converted from AA to GnRH agonists, with a median time of exposure to AA 
of 4.3 years (95% CI 4.1-4.6) (Figure 20). 
 
The 5-year cumulative incidence of prostate cancer mortality for men on AA was lower 
than men on GnRH agonists (AA 16% [95% CI 15-18%], GnRH agonists 22% [95% CI 21-
24%]). The 5-year cumulative incidence of other causes mortality than prostate cancer 
was also lower for men on AA than men on GnRH agonists (AA 17% [95% CI 15-19%] 
and GnRH agonists 27% [95% CI 25-28%]) (Figure 21). 
 
In multivariable analyses, men who received GnRH agonists had a similar risk of death 
from prostate cancer as men on AA, HR 1.08 (95% CI 0.95-1.23), but a higher risk of 
death from all causes, HR 1.23 (95% CI 1.13-1.34), compared to men on AA, Table 20. 
Stratification by prostate cancer risk category revealed similar results, with the 
exception of no difference in death from any causes in men with regional metastatic 
prostate cancer, HR 1.09 (95% CI 0.94-1.26). Symptoms at diagnosis, high T stage, high 
Gleason Grade Group and imaging at diagnosis were all associated with increased risk 
of death from prostate cancer and all causes, while presence of comorbidities and not 
married status were associated with increased risk of death from all causes, Table 21. 
 
Following propensity score matching, a total of 1,972-1,976 men were identified in 
each treatment group in the 5 imputed datasets. Similar to the results of the 
traditional multivariable Cox analyses, men on GnRH agonists had a similar risk of 
death from prostate cancer as men on AA, HR 1.09 (95% CI 0.94-1.27), but a higher risk 
of death from all causes, HR 1.25 (95% CI 1.14-1.37), Table 22. Stratification by 




with regionally metastatic prostate cancer for whom there was no difference in deaths 
from all causes.  
 
Following propensity score matching, there was no statistically significant difference in 
5-year prostate cancer-specific mortality in men on AA (19% [95% CI 17-21%]) and men 
on GnRH agonists (21% [95% CI 19-24]) whereas the 5-year overall mortality was lower 
for men on AA (32% [95% CI 30-35%]) than for men on GnRH agonists (42% [95% CI 39-
45%)]. Figure 21 shows cumulative deaths from prostate cancer and deaths from all 




Table 18. Baseline characteristics of men in PCBaSe 3.0 diagnosed  with intermediate, high-risk, regionally metastatic, or distant metastatic prostate cancer in 2006-2012 and treated 
with primary anti-androgen monotherapy (AA) or GnRH agonists. 
 
  Intermediate-risk High-risk Regionally metastatic Distant metastatic 
  AA GnRH AA GnRH AA GnRH AA GnRH 
  n = 692 n = 918 n = 1 552 n = 3 262 n = 526 n = 1 616 n = 428 n = 4 654 
  n % n % n % n % n % n % n % n % 
Year of diagnosis                 
2006-2007 144 (20.8) 337 (36.7) 371 (23.9) 1105 (33.9) 171 (32.5) 587 (36.3) 103 (24.1) 1356 (29.1) 
2008-2010 195 (28.2) 288 (31.4) 435 (28.0) 1008 (30.9) 124 (23.6) 468 (29.0) 107 (25.0) 1384 (29.7) 
2011-2012 353 (51.0) 293 (31.9) 746 (48.1) 1149 (35.2) 231 (43.9) 561 (34.7) 218 (50.9) 1914 (41.1) 
Age at diagnosis, years                 
<70 69 (10.0) 88 (9.6) 184 (11.9) 365 (11.2) 144 (27.4) 334 (20.7) 150 (35.0) 1529 (32.9) 
70-74 169 (24.4) 203 (22.1) 301 (19.4) 471 (14.4) 113 (21.5) 280 (17.3) 97 (22.7) 800 (17.2) 
75-79 303 (43.8) 321 (35.0) 549 (35.4) 939 (28.8) 139 (26.4) 348 (21.5) 77 (18.0) 866 (18.6) 
80-84 116 (16.8) 220 (24.0) 376 (24.2) 971 (29.8) 94 (17.9) 396 (24.5) 69 (16.1) 885 (19.0) 
85-90 35 (5.1) 86 (9.4) 142 (9.1) 516 (15.8) 36 (6.8) 258 (16.0) 35 (8.2) 574 (12.3) 
Mode of detection                 
Screening* 246 (35.5) 208 (22.7) 433 (27.9) 640 (19.6) 129 (24.6) 293 (18.2) 92 (21.5) 622 (13.4) 
LUTS 311 (44.9) 511 (55.7) 755 (48.7) 1932 (59.2) 261 (49.7) 904 (56.0) 198 (46.3) 1912 (41.1) 
Symptoms 109 (15.8) 146 (15.9) 311 (20.1) 594 (18.2) 120 (22.9) 372 (23.1) 127 (29.7) 1996 (42.9) 
Missing 26 (3.8) 53 (5.8) 52 (3.4) 95 (2.9) 15 (2.9) 44 (2.7) 11 (2.6) 124 (2.7) 
Clinical tumour category                 
T1a 3 (0.4) 10 (1.1) 3 (0.2) 10 (0.3) 0 (0.0) 3 (0.2) 3 (0.7) 9 (0.2) 
T1b 15 (2.2) 23 (2.5) 22 (1.4) 55 (1.7) 7 (1.3) 11 (0.7) 0 (0.0) 22 (0.5) 
T1c 261 (37.7) 342 (37.3) 297 (19.1) 465 (14.3) 77 (14.6) 175 (10.8) 50 (11.7) 341 (7.3) 
T2 413 (59.7) 543 (59.2) 503 (32.4) 1200 (36.8) 136 (25.9) 434 (26.9) 119 (27.8) 946 (20.3) 




T4 - - - - - - - - 76 (14.4) 262 (16.2) 49 (11.4) 933 (20.0) 
Missing - - - - 16 (1.0) 40 (1.2) 4 (0.8) 16 (1.0) 6 (1.4) 115 (2.5) 
N stage                 
N0 52 (7.5) 49 (5.3) 115 (7.4) 179 (5.5) 35 (6.7) 83 (5.1) 42 (9.8) 199 (4.3) 
N1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 66 (12.5) 211 (13.1) 22 (5.1) 282 (6.1) 
NX 639 (92.3) 869 (94.7) 1434 (92.4) 3074 (94.2) 423 (80.4) 1318 (81.6) 364 (85.0) 4164 (89.5) 
Missing 1 (0.1) 0 (0.0) 3 (0.2) 9 (0.3) 2 (0.4) 4 (0.2) 0 (0.0) 9 (0.2) 
M stage                 
M0 326 (47.1) 267 (29.1) 902 (58.1) 1300 (39.9) 364 (69.2) 776 (48.0) 169 (39.5) 701 (15.1) 
M1 - - - - - - - - - - - - 192 (44.9) 2979 (64.0) 
MX 366 (52.9) 651 (70.9) 650 (41.9) 1962 (60.1) 162 (30.8) 840 (52.0) 67 (15.7) 974 (20.9) 
Gleason Grade Group                 
GGG1 113 (16.3) 171 (18.6) 208 (13.4) 265 (8.1) 61 (11.6) 117 (7.2) 25 (5.8) 142 (3.1) 
GGG2 307 (44.4) 371 (40.4) 316 (20.4) 434 (13.3) 96 (18.3) 218 (13.5) 65 (15.2) 379 (8.1) 
GGG3 244 (35.3) 308 (33.6) 292 (18.8) 562 (17.2) 117 (22.2) 284 (17.6) 99 (23.1) 714 (15.3) 
GGG4 0 (0.0) 0 (0.0) 415 (26.7) 875 (26.8) 132 (25.1) 398 (24.6) 101 (23.6) 1275 (27.4) 
GGG5 0 (0.0) 0 (0.0) 238 (15.3) 923 (28.3) 90 (17.1) 454 (28.1) 104 (24.3) 1600 (34.4) 
Missing 28 (4.0) 68 (7.4) 83 (5.3) 203 (6.2) 30 (5.7) 145 (9.0) 34 (7.9) 544 (11.7) 
Percentage positive biopsy 
cores                 
0-49% 231 (33.4) 248 (27.0) 373 (24.0) 479 (14.7) 79 (15.0) 144 (8.9) 37 (8.6) 275 (5.9) 
50-74% 193 (27.9) 227 (24.7) 385 (24.8) 575 (17.6) 74 (14.1) 202 (12.5) 66 (15.4) 469 (10.1) 
75-100% 149 (21.5) 176 (19.2) 491 (31.6) 1318 (40.4) 242 (46.0) 803 (49.7) 234 (54.7) 2647 (56.9) 
Missing 119 (17.2) 267 (29.1) 303 (19.5) 890 (27.3) 131 (24.9) 467 (28.9) 91 (21.3) 1263 (27.1) 
PSA at diagnosis, ng/ml                 
<3 10 (1.4) 14 (1.5) 21 (1.4) 32 (1.0) 1 (0.2) 12 (0.7) 1 (0.2) 26 (0.6) 
3-10 264 (38.2) 290 (31.6) 222 (14.3) 431 (13.2) 16 (3.0) 52 (3.2) 11 (2.6) 129 (2.8) 
10-20 405 (58.5) 593 (64.6) 352 (22.7) 768 (23.5) 35 (6.7) 78 (4.8) 22 (5.1) 171 (3.7) 




50+ - - - - - - - - 423 (80.4) 1277 (79.0) 345 (80.6) 3822 (82.1) 
Missing 13 (1.9) 21 (2.3) 15 (1.0) 63 (1.9) 0 (0.0) 14 (0.9) 1 (0.2) 87 (1.9) 
Charlson comorbidity index                 
0 375 (54.2) 463 (50.4) 884 (57.0) 1771 (54.3) 333 (63.3) 931 (57.6) 294 (68.7) 2886 (62.0) 
1 184 (26.6) 248 (27.0) 394 (25.4) 781 (23.9) 112 (21.3) 372 (23.0) 85 (19.9) 1030 (22.1) 
2 77 (11.1) 107 (11.7) 164 (10.6) 386 (11.8) 44 (8.4) 191 (11.8) 30 (7.0) 391 (8.4) 
3+ 56 (8.1) 100 (10.9) 110 (7.1) 324 (9.9) 37 (7.0) 122 (7.5) 19 (4.4) 347 (7.5) 
Marital status                 
Married 479 (69.2) 572 (62.3) 1036 (66.8) 2080 (63.8) 352 (66.9) 977 (60.5) 268 (62.6) 2773 (59.6) 
Not married 213 (30.8) 346 (37.7) 516 (33.2) 1182 (36.2) 174 (33.1) 639 (39.5) 160 (37.4) 1881 (40.4) 
Education level                 
High 131 (18.9) 113 (12.3) 301 (19.4) 458 (14.0) 91 (17.3) 221 (13.7) 95 (22.2) 769 (16.5) 
Middle 249 (36.0) 310 (33.8) 531 (34.2) 1039 (31.9) 185 (35.2) 551 (34.1) 154 (36.0) 1590 (34.2) 
Low 304 (43.9) 488 (53.2) 705 (45.4) 1717 (52.6) 243 (46.2) 815 (50.4) 171 (40.0) 2226 (47.8) 
Missing 8 (1.2) 7 (0.8) 15 (1.0) 48 (1.5) 7 (1.3) 29 (1.8) 8 (1.9) 69 (1.5) 




Table 19. Baseline characteristics of men in PCBaSe 3.0 diagnosed with high-risk and regionally metastatic prostate cancer in 2006-2012 and treated with anti-androgen monotherapy 
or GnRH agonists. 
 
 
Raw Imputed* Propensity score matched 
 Anti-androgens GnRH agonists Anti-androgens GnRH agonists Anti-androgens GnRH agonists 
 N = 2,078 N = 4,878 N = 2,060 N = 4,740 N = 1,975 N = 1,975 
 N % N % N % N % N % N % 
Year of diagnosis 
             
2006-2007 542 (26.1) 1692 (34.7) 538 (26.1) 1638 (34.6) 527 (26.7) 547 (27.7) 
2008-2010 559 (26.9) 1476 (30.3) 548 (26.6) 1415 (29.9) 532 (26.9) 532 (26.9) 
2011-2012 977 (47.0) 1710 (35.1) 974 (47.3) 1687 (35.6) 916 (46.4) 896 (45.4) 
Age at diagnosis, years 
                       
<70 328 (15.8) 699 (14.3) 327 (15.9) 681 (14.4) 311 (15.7) 357 (18.1) 
70-74 414 (19.9) 751 (15.4) 409 (19.9) 735 (15.5) 382 (19.3) 342 (17.3) 
75-79 688 (33.1) 1287 (26.4) 682 (33.1) 1247 (26.3) 654 (33.1) 548 (27.7) 
80-84 470 (22.6) 1367 (28.0) 464 (22.5) 1323 (27.9) 454 (23.0) 485 (24.6) 
85-90 178 (8.6) 774 (15.9) 178 (8.6) 754 (15.9) 174 (8.8) 243 (12.3) 
Mode of detection 
             




(48.9) 2836 (58.2) 1045 (50.7) 2852 (60.2) 1021 (51.7) 1058 (53.6) 
Symptoms 431 (20.8) 966 (19.8) 440 (21.4) 952 (20.1) 418 (21.2) 407 (20.6) 
Missing 67 (3.2) 139 (2.9) 
         
Clinical tumour category 
                       
 
                       
T1a 3 (0.1) 13 (0.3) 3 (0.1) 13 (0.3) 3 (0.2) 2 (0.1) 
T1b 29 (1.4) 66 (1.4) 30 (1.5) 66 (1.4) 30 (1.5) 28 (1.4) 
T1c 374 (18.0) 640 (13.1) 375 (18.2) 639 (13.5) 342 (17.3) 335 (17.0) 




T3 937 (45.1) 2207 (45.2) 932 (45.2) 2157 (45.5) 897 (45.4) 882 (44.7) 
T4 76 (3.7) 262 (5.4) 75 (3.6) 253 (5.3) 74 (3.7) 76 (3.8) 
TX 20 (1.0) 56 (1.1)                 
N stage 
             
N0 150 (7.2) 262 (5.4) 150 (7.3) 263 (5.5) 145 (7.3) 133 (6.7) 




(89.4) 4392 (90.0) 1844 (89.5) 4270 (90.1) 1764 (89.3) 1778 (90.0) 
Missing 5 (0.2) 13 (0.3) 
         
Gleason Grade Group 
                       
GGG1 269 (12.9) 382 (7.8) 274 (13.3) 394 (8.3) 254 (12.9) 221 (11.2) 
GGG2 412 (19.8) 652 (13.4) 444 (21.6) 725 (15.3) 415 (21.0) 385 (19.5) 
GGG3 409 (19.7) 846 (17.3) 433 (21.0) 908 (19.2) 410 (20.8) 410 (20.8) 
GGG4 547 (26.3) 1273 (26.1) 564 (27.4) 1308 (27.6) 552 (27.9) 568 (28.8) 
GGG5 328 (15.8) 1377 (28.2) 345 (16.7) 1405 (29.6) 344 (17.4) 391 (19.8) 
Missing 113 (5.4) 348 (7.1)                 
Percent positive biopsy 
cores 
           
0-49% 452 (21.8) 623 (12.8) 570 (27.7) 838 (17.7) 528 (26.7) 507 (25.7) 
50-74% 459 (22.1) 777 (15.9) 562 (27.3) 1049 (22.1) 526 (26.6) 499 (25.3) 
75-100% 733 (35.3) 2121 (43.5) 928 (45.0) 2853 (60.2) 921 (46.6) 969 (49.1) 
Missing 434 (20.9) 1357 (27.8) 
         
PSA at diagnosis, ng/ml 
                       
<3 22 (1.1) 44 (0.9) 23 (1.1) 43 (0.9) 23 (1.2) 18 (0.9) 
03-Oct 238 (11.5) 483 (9.9) 238 (11.6) 477 (10.1) 223 (11.3) 230 (11.6) 
Oct-20 387 (18.6) 846 (17.3) 388 (18.8) 840 (17.7) 376 (19.0) 376 (19.0) 
20-50 993 (47.8) 2151 (44.1) 988 (48.0) 2111 (44.5) 936 (47.4) 936 (47.4) 
50+ 423 (20.4) 1277 (26.2) 423 (20.5) 1269 (26.8) 417 (21.1) 415 (21.0) 
Missing 15 (0.7) 77 (1.6)                 
CCI 







(58.6) 2702 (55.4) 1206 (58.5) 2618 (55.2) 1148 (58.1) 1168 (59.1) 
1 506 (24.4) 1153 (23.6) 501 (24.3) 1124 (23.7) 486 (24.6) 459 (23.2) 
2 208 (10.0) 577 (11.8) 206 (10.0) 565 (11.9) 199 (10.1) 205 (10.4) 
3+ 147 (7.1) 446 (9.1) 147 (7.1) 433 (9.1) 142 (7.2) 143 (7.2) 
Marital status 




(66.8) 3057 (62.7) 1375 (66.7) 2969 (62.6) 1315 (66.6) 1335 (67.6) 
Not married 690 (33.2) 1821 (37.3) 685 (33.3) 1771 (37.4) 660 (33.4) 640 (32.4) 
Education level 
             
High 392 (18.9) 679 (13.9) 394 (19.1) 670 (14.1) 367 (18.6) 335 (17.0) 
Middle 716 (34.5) 1590 (32.6) 717 (34.8) 1564 (33.0) 682 (34.5) 689 (34.9) 
Low 948 (45.6) 2532 (51.9) 949 (46.1) 2506 (52.9) 926 (46.9) 951 (48.2) 
Missing 22 (1.1) 77 (1.6)                 




Table 20. Risk of death from prostate cancer or death from all causes in men on primary anti-androgen monotherapy or GnRH agonists. 
  
All men with high-risk and regionally 
metastatic prostate cancer 
Men with high-risk*prostate cancer 




prostate cancer  
Death from all 
causes  
Death from 
prostate cancer  
Death from all causes  
Death from 
prostate cancer  
Death from all causes  
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Anti-androgen 
monotherapy 
1.00 (Ref) 1.00 (Ref)                 
GnRH agonists              
Crude model using age as 
time scale 
1.39 (1.23-1.57) 1.45 (1.34-1.57) 1.45 (1.24-1.69) 1.50 (1.37-1.65) 1.16 (0.96-1.42) 1.26 (1.09-1.46) 
Adjustment              
     T stage  1.37 (1.21-1.55) 1.45 (1.34-1.57) 1.44 (1.23-1.68) 1.51 (1.37-1.66) 1.16 (0.95-1.41) 1.26 (1.09-1.46) 
  + Gleason Grade Group  1.21 (1.07-1.37) 1.37 (1.27-1.48) 1.25 (1.07-1.47) 1.44 (1.30-1.58) 1.06 (0.87-1.29) 1.19 (1.03-1.37) 
  + PSA*** 1.19 (1.05-1.34) 1.36 (1.25-1.47) 1.24 (1.06-1.46) 1.43 (1.30-1.57) 1.04 (0.85-1.27) 1.18 (1.02-1.36) 
  + Proportion positive 
biopsy cores**** 
1.15 (1.01-1.30) 1.34 (1.23-1.45) 1.19 (1.01-1.39) 1.40 (1.27-1.55) 1.02 (0.84-1.25) 1.17 (1.01-1.35) 
  + Imaging performed 1.11 (0.98-1.25) 1.29 (1.19-1.40) 1.15 (0.98-1.34) 1.36 (1.23-1.50) 0.96 (0.79-1.18) 1.11 (0.96-1.29) 
  + Time between 
diagnosis and start of 
treatment  
1.11 (0.98-1.26) 1.29 (1.19-1.40) 1.15 (0.98-1.35) 1.36 (1.23-1.50) 0.97 (0.79-1.18) 1.11 (0.95-1.28) 
  + Mode of detection 1.10 (0.97-1.25) 1.28 (1.18-1.39) 1.13 (0.96-1.33) 1.34 (1.21-1.48) 0.96 (0.78-1.18) 1.10 (0.95-1.28) 
  + Year of diagnosis 1.09 (0.96-1.23) 1.27 (1.17-1.38) 1.12 (0.95-1.31) 1.33 (1.20-1.47) 0.96 (0.78-1.17) 1.10 (0.95-1.28) 
  + CCI 1.08 (0.96-1.23) 1.25 (1.15-1.36) 1.11 (0.95-1.31) 1.30 (1.18-1.43) 0.96 (0.78-1.17) 1.10 (0.95-1.27) 
  + Marital status 1.08 (0.96-1.23) 1.24 (1.14-1.35) 1.11 (0.95-1.31) 1.29 (1.17-1.43) 0.96 (0.78-1.17) 1.09 (0.94-1.26) 
  + Education 1.08 (0.95-1.23) 1.23 (1.13-1.34) 1.11 (0.94-1.31) 1.28 (1.16-1.41) 0.96 (0.78-1.17) 1.09 (0.94-1.26) 
 
Hazard ratios calculated by use of Cox regression analyses 
* High-risk prostate cancer: T3 and/or PSA 20 ng/ml or higher and lower than 50 ng/ml and/or Gleason Grade Group 4-5 
** Regionally metastatic prostate cancer: T4 and/or PSA 50 ng/ml or higher and lower than 100 ng/ml or N1 
*** Modelled using a linear spline with knots in PSA 3, 10, 20 and 50 




Table 21. Risk of death from prostate cancer or death from all causes in men treated with primary anti-androgen monotherapy or GnRH agonists. 
  
All men with high-risk and regional 
metastatic prostate cancer 
Men with high-risk prostate cancer Men with regional metastatic prostate cancer 
  Death from all causes  
Death from 
prostate cancer 
Death from all causes  
Death from prostate 
cancer  
Death from all causes 
Death from prostate 
cancer  
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Treatment                         
   Anti-androgen 
monotherapy  
1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   GnRH agonists  1.23 (1.14-1.34) 1.09 (0.96-1.24) 1.12 (0.95-1.32) 1.28 (1.16-1.42) 0.96 (0.79-1.18) 1.09 (0.94-1.27) 
Clinical tumuor category              
   T1a/ T1b 0.99 (0.74-1.32) 1.68 (1.14-2.48) 1.64 (1.04-2.58) 0.99 (0.71-1.39) 1.79 (0.78-4.11) 1.11 (0.58-2.13) 
   T1c 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
    T2 1.01 (0.91-1.13) 1.13 (0.93-1.37) 1.06 (0.84-1.34) 1.00 (0.88-1.14) 1.26 (0.90-1.76) 1.09 (0.87-1.35) 
    T3 1.14 (1.02-1.27) 1.28 (1.06-1.55) 1.28 (1.01-1.62) 1.13 (0.99-1.28) 1.30 (0.93-1.82) 1.17 (0.95-1.45) 
    T4 1.48 (1.24-1.77) 1.91 (1.46-2.50) NA NA NA NA 1.32 (0.87-1.98) 1.28 (0.98-1.68) 
Gleason Grade Group                         
    GGG 1 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
    GGG 2 1.11 (0.96-1.29) 1.43 (1.08-1.90) 1.48 (1.02-2.17) 1.03 (0.86-1.22) 1.36 (0.89-2.07) 1.38 (1.05-1.82) 
    GGG 3 1.29 (1.12-1.49) 1.72 (1.32-2.25) 1.67 (1.15-2.42) 1.13 (0.95-1.33) 1.72 (1.14-2.59) 1.76 (1.34-2.31) 
    GGG 4 1.39 (1.22-1.60) 2.34 (1.79-3.06) 2.50 (1.74-3.60) 1.23 (1.04-1.44) 2.17 (1.46-3.23) 1.91 (1.47-2.49) 
    GGG 5 1.75 (1.53-2.02) 3.44 (2.63-4.50) 3.89 (2.68-5.64) 1.56 (1.32-1.83) 2.92 (1.97-4.32) 2.36 (1.82-3.08) 
Proportion positive biopsy 
cores * 
             
    <50% 0.90 (0.80-1.02) 0.76 (0.63-0.92) 0.74 (0.58-0.94) 0.93 (0.82-1.06) 0.84 (0.53-1.31) 0.83 (0.62-1.10) 
    50-74% 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   75-89% 1.00 (0.84-1.18) 1.01 (0.78-1.31) 1.03 (0.78-1.37) 1.06 (0.88-1.27) 0.95 (0.57-1.56) 0.87 (0.66-1.15) 
   90+% 1.07 (0.95-1.20) 1.16 (0.98-1.37) 1.18 (0.94-1.47) 1.09 (0.96-1.25) 1.09 (0.81-1.48) 0.97 (0.78-1.19) 
PSA at diagnosis, ng/mL                         




   3-10 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   10-20 0.98 (0.86-1.12) 0.96 (0.77-1.19) 0.99 (0.78-1.27) 1.00 (0.87-1.15) 0.77 (0.47-1.25) 0.83 (0.56-1.21) 
   20-50 1.07 (0.95-1.20) 1.01 (0.84-1.22) 1.07 (0.87-1.32) 1.10 (0.97-1.24) 0.74 (0.48-1.14) 0.68 (0.48-0.97) 
   50+ 1.16 (1.02-1.31) 1.27 (1.03-1.55) 1.46 (0.34-6.25) 1.13 (0.30-4.23) 0.54 (0.36-0.82) 0.68 (0.49-0.94) 
Mode of detection              
   Screening 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   LUTS 1.28 (1.16-1.41) 1.44 (1.22-1.70) 1.42 (1.15-1.76) 1.28 (1.14-1.44) 1.43 (1.11-1.85) 1.24 (1.05-1.46) 
   Symptoms 1.37 (1.22-1.53) 1.51 (1.25-1.83) 1.40 (1.10-1.79) 1.34 (1.17-1.55) 1.61 (1.21-2.15) 1.40 (1.16-1.70) 
Bone imaging performed                         
   No 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   Yes 0.87 (0.81-0.94) 0.86 (0.77-0.97) 0.86 (0.74-1.01) 0.88 (0.80-0.97) 0.75 (0.62-0.91) 0.80 (0.70-0.92) 
Year of diagnosis, 
0.97 (0.95-0.99) 0.95 (0.92-0.98) 0.95 (0.91-0.99) 0.97 (0.94-0.99) 0.98 (0.93-1.02) 0.98 (0.95-1.01) 
By one year increase 
Time from diagnosis to 
treatment initiation, by six 
month delay 
1.00 (0.99-1.01) 1.01 (1.00-1.02) 1.00 (0.99-1.02) 1.00 (0.99-1.01) 1.00 (0.99-1.02) 1.00 (0.99-1.01) 
Charlson comorbidity index                         
0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
1 1.21 (1.12-1.32) 0.96 (0.84-1.10) 0.91 (0.76-1.08) 1.18 (1.07-1.31) 1.06 (0.87-1.30) 1.26 (1.09-1.45) 
2 1.46 (1.31-1.62) 0.82 (0.68-1.00) 0.89 (0.70-1.12) 1.45 (1.27-1.64) 0.73 (0.52-1.02) 1.47 (1.21-1.78) 
   3+ 1.88 (1.68-2.09) 1.08 (0.88-1.32) 1.16 (0.91-1.48) 2.06 (1.81-2.33) 0.99 (0.68-1.42) 1.49 (1.19-1.87) 
Marital status              
   Married 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   Not married 1.08 (1.00-1.15) 1.00 (0.89-1.11) 1.00 (0.87-1.15) 1.08 (0.99-1.17) 1.04 (0.87-1.23) 1.09 (0.97-1.23) 
Education level                         
   High 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 
   Middle 1.18 (1.06-1.30) 1.03 (0.88-1.19) 1.02 (0.84-1.24) 1.22 (1.08-1.38) 1.05 (0.82-1.34) 1.07 (0.90-1.28) 
   Low 1.07 (0.96-1.19) 0.98 (0.84-1.15) 0.98 (0.80-1.20) 1.12 (0.98-1.27) 1.00 (0.77-1.28) 0.99 (0.82-1.18) 
Hazard ratios calculated by use of Cox regression analyses.  





Table 22. Risk of death from prostate cancer or death from all causes for men on primary GnRH agonists or anti-androgen monotherapy (AA, reference in analyses) following propensity 
score matching. 
  Including all men with a match 
 
Number of men in group* No of events Crude Adjusted 
 
 AA GnRH HR 95% CI HR 95% CI 
High-risk and regionally metastatic prostate cancer        
Death from prostate cancer 1975 348 371 1.09 (0.94-1.26) 1.05 (0.90-1.23) 
Death from all causes 1975 702 858 1.25 (1.13-1.38) 1.23 (1.11-1.36) 
High-risk prostate cancer**        
Death from prostate cancer 1436 209 239 1.15 (0.91-1.45) 1.12 (0.88-1.42) 
Death from all causes 1436 473 619 1.33 (1.18-1.50) 1.29 (1.14-1.46) 
Regionally metastatic prostate cancer***        
Death from prostate cancer 506 132 123 0.96 (0.72-1.28) 0.93 (0.69-1.43) 
Death from all causes 506 215 237 1.11 (0.89-1.37) 1.12 (0.89-1.40) 
Hazard ratios calculate by use of Cox regression analyses. The median time from diagnosis to start of treatment was 16 days longer for men on AA compared to men on GnRH agonists 
*Number of men in the first of the imputed dataset 
** High-risk prostate cancer: T3 and/or PSA 20 ng/ml or higher and lower than 50 ng/ml and/or Gleason Grade Group 4-5 
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4.4.4. Discussion  
In this register-based, observational study of men with advanced, non-metastatic 
prostate cancer treated with primary hormonal therapy, men on AA had similar 
prostate cancer mortality and lower all-cause mortality than men on GnRH agonists. 
 
As previously mentioned two RCTs conducted in the 1990s showed similar risk of 
prostate cancer death in men with advanced, non-metastatic prostate cancer on AA 
and men on GnRH agonists (169, 170). Even though RCTs are considered the gold 
standard for comparisons of treatments, when it comes to show clinical effectiveness 
observational studies are more accurate (273). The guidelines from the European 
GetReal consortium ("incorporating real-life data into drug development") specifically 
recommend considering evidence from pragmatic trials and non-randomised studies 
to improve applicability of treatment effect estimates, inform disconnected or scarce 
networks of evidence, identify patient populations that will likely receive the drug after 
launch, and to improve relevant to decision/policy makers and patients (276). Given 
that including more patients in an observational study may be associated with a low 
cost, usually these studies count with large number of participants who may be more 
representative of the general population. For instance, in the RCTs mentioned before 
there were 320 patients recruited in one and 480 in the other versus 6,956 from this 
study. Furthermore, some of the RCTs limitations include: high selectivity of 
participants enrolled which results in an underrepresentation of individuals seen in 
practice in certain characteristics like age, comorbidities, and socioeconomic status 
(277, 278). In the current register-based, observational study, all men with relevant 
cancer characteristics were included regardless of other characteristics, with the 
exception of very high age (>90 years) and a previous cancer diagnosis. 
 
A general limitation of observational studies comparing the outcome of treatment is 
the possibility of channelling bias or confounding by indication. Confounding by 
indication may occur if the factors associated with the indication for treatment are also 
associated with the outcome under study.  In the current study, men managed with AA 
were younger, diagnosed in more recent calendar years and had less adverse cancer 




be associated with a lower mortality. We adjusted for these differences in the 
traditional Cox regression analyses and found that the results were in line with 
previous RCTs with similar risk of prostate cancer death in men on AA and men on 
GnRH agonists (169, 170). However, lower all-cause mortality among men treated with 
AA was also observed. Unaccounted confounders are likely to explain some of this 
difference, as it can be hypothesised that in a clinical setting, results from treatment 
with AA will be better than for GnRH agonists because men on AA have smaller cancer 
burden and lower comorbidity resulting in a lower risk of death from all causes.  
 
In order to account for differences between treatment groups that could cause 
confounding by indication propensity scores were calculated for the propensity of AA 
treatment. These scores were used to match groups of men on AA and men on GnRH 
agonists respectively. One limitation propensity score matching has in common with 
traditional multivariable Cox regression analyses is the inability to adjust for 
unmeasured confounders. However, a matched propensity score analysis excludes 
exposed participants who have no comparable unexposed participant and vice versa 
(279). Propensity score matching does not assume linearity in the relationship 
between the propensity and outcome and allows for simple, transparent analyses. It 
provides a better balance of covariates between exposed and unexposed groups 
compared to other matching strategies in datasets with many covariates (280). 
Interestingly, the propensity score matched analyses revealed similar results as the 
traditional multivariable Cox regression analyses.  
 
Considering that we have applied methods used to reduce confounding and make the 
comparison groups as similar as possible in baseline characteristics, our results suggest 
that the found differences are likely to be due to the drugs mechanism of action and 
side effects. More specifically, antiandrogens are known to block the androgen 
receptor, with androgen levels remaining normal, whereas GnRH agonists lower 
androgen levels. Low levels of androgens have been associated with increased levels of 
LDL, triglycerides and insulin, all risk factors of CVD (281). Furthermore, testosterone 
may have a protective effect against the development of atheroma through coronary 




The GnRH receptor is expressed on T lymphocytes, which can be found in atheroma. T-
cell activation upon application of GnRH agonists has been observed in experimental 
studies. Plaque instability can increase the risk of thrombo-embolic complications 
(283-285). 
 
As mentioned above, a main limitation of the present study is the non-random 
allocation to type of hormonal therapy, with ensuing possible confounding by 
indication and illustrated by younger and healthier men with less advanced cancer to 
receive AA. However, as previously discussed use of propensity score matching did not 
alter the main findings. In a recent study using STAMPEDE data, authors found that 
high-risk non-metastatic prostate cancer two-year survival was 96% (95% CI, 93%-97%) 
and 2-year failure free survival was 77% (95% CI, 73%-81%). Median failure free 
survival was 63 months. Therefore, a potential further limitation of the present study 
may be a short follow up period (286).  
 Strengths of this study include the nationwide, population-based cohort of men with 
comprehensive data from a clinical cancer register with documented high data quality 
as well as several other high-quality health care registers (287, 288) a setting that thus 
provides strong real-world data.  
 
4.4.5. Conclusion 
In men with advanced, non-metastatic prostate cancer, prostate cancer-specific 
mortality was similar and all-cause mortality was lower in men primarily treated with 
AA compared to men treated with GnRH agonists. Our data provide further support for 







5. Chapter 5: Conclusion and future directions 
When I started this thesis, I wanted to investigate the impact of a prostate cancer 
diagnosis and its treatments on a man’s quality and quantity of life, by looking at less 
understood and studied exposures and outcomes. Overall, the findings of all projects 
involved helped generate hypotheses and ideas for future studies. In the following 
section, I give a brief summary of each of my projects results followed by proposals for 
follow-up projects to be carried out in the near future. 
 
To the best of my knowledge, my findings in the AMORIS study of an association 
between elevated lipid levels and GGT and SDPTs are the first of its kind and call for 
further investigation. However, it is important to highlight that variation in lipid levels 
and GGT may be a proxy for other exposures, such as  lifestyle factors, which were only 
taken into account by use of the Charlson Comorbidity Index. Hence, the current 
findings may reflect the association between any other unknown biological changes 
and the risk of SDPTs. Whether these biomarkers alterations caused further changes 
that led to carcinogenesis or are a common underlying alteration remains unknown. 
Hence, pre-clinical studies are necessary to support the findings and related generated 
hypothesis.  
 
The findings from the radiotherapy and thromboembolic events project are also the 
first of its kind. As mentioned before, it is important to acknowledge study limitations, 
such as the impossibility to present subgroup analysis according to the type of external 
beam radiotherapy or brachytherapy and the rather short follow up period. Therefore, 
a follow-up of this study is of interest to further establish if type of radiotherapy, dose 
of radiotherapy, or longer time after exposure affect the current findings.  
 
My study on ‘metabolic drugs’ and prostate cancer death and overall mortality 
amongst men treated with GnRH agonists is also one of the few studies currently 
investigating this question. So far, most studies focused on the use of metabolic drugs 
after GnRH agonists initiation in the context of adverse effects. Therefore, my results 




contraindication for GnRH agonists. However, as this was an observational study, it 
remains difficult to tease out whether I studied the metabolic symptoms or their 
related drugs.  
 
My findings in the last project provided support that antiandrogens might be an 
alternative to GnRH agonists. When physicians and patients have the option to use 
different medications, understanding how they compare in terms of efficacy and 
adverse effects is key. Given the diversity of drugs available for men with advanced 
prostate cancer, it would be of interest to design studies where all these drugs are 
compared with a focus on both cancer specific (prostate cancer death, progression) 
and treatment-related outcomes (side effects).  
 
In conclusion, the current thesis provides more insight into how prostate cancer and its 
treatments affect the quality and quantiy of life of men with prostate cancer. For each 
of the projects the following are potential follow-up studies:   
 
(1) Longitudinal studies using the lifecourse approach to get a better 
understanding of how different metabolisms are associated with development 
of different cancers 
(2) Assessment of TED risk comparing different types and dosages of radiotherapy 
(3) Window-of-opportunity trials to identify how drugs for metabolic components 
or the metabolic factors themselves are biologically affecting prostate cancer 
progression in the context of other prostate cancer treatments 
(4) Inclusion of anti-androgen monotherapy as a treatment arm in future RCTs for 
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